Conformational changes in ezrin analyzed by Förster resonance energy transfer by Shabardina, V. (Victoria)
  
 
 
 
 
Conformational changes in ezrin analyzed by 
Förster resonance energy transfer 
 
 
 
 
 
 
 
 
Dissertation 
am Fachbereich Biologie der Universität Münster 
 
 
Victoria Shabardina 
 
2015
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Biologie 
 
 
Conformational changes in ezrin analyzed by 
Förster resonance energy transfer 
 
 
 
 
 
 
 
 
 
Inaugural-Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften im Fachbereich Biologie 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Westfälischen Wilhelms-Universität Münster 
 
 
vorgelegt von 
Victoria Shabardina 
Aus Kirov 
2015 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan:     Prof. Dr. Wolf-Michael Weber 
 
Erster Gutachter:    Prof. Dr. Volker Gerke 
 
Zweiter Gutachter:   Prof. Dr. Martin Bähler  
 
Tag der mündlichen Prüfung:               8.12.2015 
Tag der Promotion:            18.12.2015 
 
 
  
  
 
  
I 
 
 
Contents 
Summary ......................................................................................................................................... V 
1 Introduction .................................................................................................................................... 1 
1.1 The ERM protein family ................................................................................................................ 1 
1.2  ERM proteins and their conservative features ............................................................................ 1 
1.3 Ezrin is involved in cell cortex organization and signaling cascades ............................................. 4 
1.4 Dormant and activated states of ezrin.......................................................................................... 7 
1.4.1 Role of PIP2 in the cell ............................................................................................................. 8 
1.4.2 Protein phosphorylation as one of the main regulators of cell functioning ............................. 10 
1.4.3 Structure and conformations of ezrin ..................................................................................... 11 
1.5 Ezrin activation hypothesis ......................................................................................................... 16 
1.6  Aim of the study and general experimental approach .............................................................. 20 
2 Materials ....................................................................................................................................... 25 
2.1 Chemicals and reagents .............................................................................................................. 25 
2.2 Markers ....................................................................................................................................... 26 
2.3 Kits ............................................................................................................................................... 26 
2.4 Antibodies ................................................................................................................................... 27 
2.5  Enzymes ..................................................................................................................................... 27 
2.6 Cell lines ...................................................................................................................................... 27 
2.7 Bacterial strains ........................................................................................................................... 28 
2.8 DNA-constructs ........................................................................................................................... 28 
2.8.1 Eukaryotic and bacterial expression vectors ........................................................................... 28 
2.8.2 Oligonucleotides .................................................................................................................... 29 
2.9 Equipment ................................................................................................................................... 29 
2.10 Devices ...................................................................................................................................... 29 
3 Methods ........................................................................................................................................ 31 
3.1 Cell biology methods ................................................................................................................... 31 
3.1.1 Cultivation of adherent eukaryotic cells .................................................................................. 31 
3.1.2 Cryo-stocks ............................................................................................................................ 31 
3.1.3 EGF stimulation experiments ................................................................................................ 31 
3.1.4 Confocal immunofluorescence imaging.................................................................................. 31 
3.1.5 Transient transfection ............................................................................................................ 32 
3.1.6 Stable transfection ................................................................................................................. 33 
II 
 
3.2 Molecular biology methods ........................................................................................................ 33 
3.2.1 Plasmids cloning .................................................................................................................... 33 
3.2.2 Maxi-preps ............................................................................................................................. 36 
3.3 Biochemical methods .................................................................................................................. 36 
3.3.1 SDS-PAGE ........................................................................................................................... 36 
3.3.2 Western Blot analysis ............................................................................................................. 37 
3.3.3 DNA gel-electrophoresis ....................................................................................................... 38 
3.3.4 Bacterial expression and purification of the proteins .............................................................. 39 
3.3.5 Recombinant expression and purification of proteins from HEK293-T cells ......................... 40 
3.3.6 Fluorescent labeling of proteins ............................................................................................. 41 
3.3.7 Bradford assay ....................................................................................................................... 42 
3.3.8 Liposomes preparation .......................................................................................................... 42 
3.3.9 Liposomes pelleting assay ...................................................................................................... 42 
3.3.10 Supported lipid bilayer preparation and protein binding ....................................................... 43 
3.3.11 Reflectometric Interference Spectroscopy - RIfS .................................................................. 44 
3.3.12 Intra- and inter-molecular FRET on supported lipid bilayers ............................................... 44 
3.3.13 Enzymatic protein digest ...................................................................................................... 45 
4 Results ................................................................................................................................................ 47 
4.1 Expression and purification of the recombinant ezrin, ezrinT567D and their GFP-fused 
derivatives using the BL21 strain of E.coli and HEK293T cells .......................................................... 48 
4.2 Liposome pelleting assay: the fluorescent derivatives of ezrin bind to PIP2 and DOGS-Ni-NTA 
containing liposomes like the wild type protein ............................................................................... 50 
4.3 EzrGFP and DGFP are recruited to the cell membrane in EGF activated A431 cells similar to 
endogenous ezrin .............................................................................................................................. 51 
4.4 DyLight405EzrGFP is not suitable for FRET analysis ................................................................... 55 
4.5 Cy3EzrGFP shows FRET ............................................................................................................... 56 
4.6 Reflectometric Interference Spectroscopy (RIfS) showes binding of the Cy3-labeled ezrin 
derivatives to PIP2- and DOGS-Ni-NTA-containing SSLB ................................................................... 59 
4.7 Fluorescent spectra, FRET in solution ......................................................................................... 61 
4.8 Analysis of FRET efficiency on solid supported bilayers ............................................................. 64 
5 Discussion ...................................................................................................................................... 73 
5.1 GFP-tag does not change properties of ezrin in the cells and in in vitro binding assays ............ 73 
5.2 Properties of Cy3EzrGFP and DyLight405EzrGFP as FRET constructs ......................................... 75 
5.3 PIP2 binding and threonine 567 phosphorylation contribute to conformational change in ezrin 
simultaneously .................................................................................................................................. 76 
III 
 
References ............................................................................................................................................ 81 
Supplemental materials ........................................................................................................................ 91 
Abbreviations ...................................................................................................................................... 105 
Acknowledgements ............................................................................................................................. 107 
Curriculum vitae ................................................................................ Fehler! Textmarke nicht definiert. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
V 
 
Summary 
Ezrin, a member of the ERM (Ezrin-Radixin-Moesin) protein family, serves as a linker 
between cell membrane and cytoskeleton in the cells of all protozoans. Thereby, it is 
involved in cell motility, cell division, cell-cell adhesion and the maintainance of cell polarity. 
Ezrin comprises two functionally important domains, the N-ERMAD (N-terminal ERM 
association domain) that contains binding sites for the membrane lipid PIP2 
(phosphatidylinositol-4,5-bisphosphate) and several membrane proteins and the C-ERMAD 
(C-terminal ERM association domain) that contains an actin binding site (ABS). In resting 
cells ezrin exists in a so-called dormant state, where most of its binding sites, including the 
ABS, are masked by an autoinhibitory association between N-ERMAD and C-ERMAD. Cell 
stimulation can lead to an activation of ezrin’s membrane-actin crosslinking function. This is 
achieved by a disruption of the N-ERMAD/C-ERMAD association and the unmasking of the 
membrane protein and F-actin binding sites. Ezrin activation is thought to be triggered by 
interaction with PIP2 and phosphorylation of a conservative threonine at position 567 in the 
C-ERMAD, but the contribution of the each activation factor is not fully understood yet. In 
this study we probed ezrin’s conformational state by FRET (Förster resonance energy 
transfer) and showed that disruption of the N-ERMAD/C-ERMAD association occurs through 
a combination of the action of both activating factors.  
FRET on solid supported lipid bilayers (SSLB) was used here for the first time to detect 
conformational changes in ezrin upon its activation. Ezrin fluorescent constructs containing 
a C-terminal eGFP tag and an N-terminally crosslinked Cy3 dye were generated and 
employed in FRET experiments following binding to SSLB. The SSLB contained either PIP2 or 
DOGS-Ni-NTA which allowed an interaction with a His tag present in all constructs. In 
addition to wild type ezrin, a Cy3-ezrinT567D-eGFP construct, mimicking ezrin’s 
phosphorylated state, was employed in the FRET experiments. Both double-labeled 
constructs, the wild type and phosphomimicking mutant, were shown to produce FRET 
signals when bound to DOGS-Ni-NTA-containing SSLB indicating a close proximity of Cy3 and 
the eGFP tag in the dormant conformation of ezrin. Upon binding to PIP2-containing SSLB, 
the efficiency of FRET decreased, suggesting that the Cy3 and eGFP had moved apart most 
likely due to a disruption of the N-C association in the protein. The strongest FRET efficiency 
drop was observed for the phosphomimicking ezrin construct Cy3-ezrinT567D-eGFP bound 
to PIP2-containing SSLB. These findings demonstrate that, although PIP2-binding alone 
appears to induce some change in the ezrin conformation, phosphorylation at threonine 
567 is necessary for a complete disruption of the N-ERMAD–C-ERMAD association. 
Together, these findings are in line with a two-step ezrin activation model that requires 1) 
PIP2 binding to unmask threonine 567 and 2) subsequent threonine 567 phosphorylation.  
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1 Introduction 
 
1.1 The ERM protein family 
 
Ezrin is a member of the ERM (Ezrin, Radixin, Moesin) protein group which belong to the 
band 4.1 protein superfamily. The first protein discovered in this superfamily was isolated 
from erythrocytes membrane and named protein 4.1, referring to the relative mobility of 
the protein band resulting from SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) separation (Yu, Fischman, and Steck 1973). It was shown to provide 
mechanical stability to the membrane. Later, other related proteins were identified, 
constituting a larger superfamily of 5 gene families, including tyrosine phosphatase PTPH1, 
the tumor suppressor merlin, ezrin, radixin, moesin – cytoskeleton-cell membrane linker 
proteins, and others. Despite their functional diversity band 4.1 superfamily members share 
a common feature, the conserved FERM-domain (4.1 ERM domain) that provides binding to 
membrane proteins and the phospholipid PIP2, suggesting that all superfamily members 
perform their functions in association with the membrane (K Takeuchi et al. 1994). The 
FERM-domain of ezrin, radixin and moesin has binding activity also towards their own C-
terminal region. This interaction causes an auto-inhibited conformational state, preventing 
the ERMs from binding to their interaction partners.  
Ezrin (less known as cytovillin or p81) was the first protein identified with homology to 
the 4.1 protein, it’s FERM domain has 30% sequence similarity with the FERM domain of 4.1 
protein (Conboy et al. 1986; Gould et al. 1989). Ezrin was found in intestinal epithelial cells 
as a major protein of microvilli of the intestinal brush border (A Bretscher 1983; Pakkanen et 
al. 1987). Later radixin was discovered in adherens junctions isolated from rat liver cells, 
moesin was first isolated from bovine uteri and characterized as a heparin-binding protein 
(W. Lankes, Griesmacher, Grünwald, Schwartz-Albiez, & Keller, 1988; Tsukita & Hieda, 1989). 
 
 
1.2  ERM proteins and their conservative features 
 
ERM proteins are present in all sequenced metazoans, but are not found in unicellular 
organisms, such as yeasts. This implies that ERM evolved in animal cells for maintaining 
multi-cellularity and regulating cell-cell interaction. Invertebrates express only one isoform, 
vertebrates have three: ezrin, radixin, moesin. These three proteins are 75% homologous in 
the whole sequence with 85% homology in the FERM domain (Funayama et al. 1991; W. T. 
Lankes and Furthmayr 1991). Furthermore, comparisons of ERM sequence among 
vertebrates and invertebrates yield striking results: the ERM homologues in Drosophila 
melanogaster (Dmoesin) and Caenorhabditis elegans (ERM-1) share 76% sequence 
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homology with human ezrin (Monique Arpin et al. 2011) and are thought to be evolutionary 
progenitors of the human ERM (Van Fürden et al. 2004). In general, ERM proteins branched 
from a common ancestor protein for the whole 4.1 superfamily late in evolutionary history 
of the band 4.1 group (see Fig.1) (K Takeuchi et al. 1994). Ezrin, radixin and moesin emerged 
by gene duplication (Verena Niggli and Rossy 2008); their genes are located on 
chromosomes 6, 11 and 10, respectively. The three isoforms are found in most tissues, 
although ezrin is preferably expressed in epithelial cells, moesin in endothelial cells and 
leucocytes, and radixin shows high expression levels in liver. At the same time the 
localization in near-membrane regions rich in associated actin (i.e. microvilli, ruffling 
membranes, adhesion sites, cleavage furrow) is characteristic for all three proteins (Sato et 
al. 1992). The main function of ERM proteins is serving as membrane-cytoskeleton linkages: 
the N-terminal ERM association domain (N-ERMAD), which corresponds to the FERM 
domain, can interact with several membrane proteins, while the C-terminal ERM association 
domain (C-ERMAD) carries an actin binding site (Algrain, Turunen, Vaheri, Louvard, & Arpin, 
1993; M Arpin, Algrain, & Louvard, 1994; Yao, Cheng, Forte, & Cell, 1996). In the 
autoinhibited or dormant form of ezrin its N-ERMAD and C-ERMAD are bound to each other, 
masking most of the other proteins binding sites (Pearson et al. 2000). The transition to the 
activated or open conformation, according to the most prevalent of existing hypotheses, is 
facilitated by an interaction with membrane PIP2 via a PIP2-binding site in the N-ERMAD and 
phosphorylation of a C-terminal threonine (Nakamura et al. 1999). The phenomenon of 
ezrin activation is central in this work and will be discussed in details further. 
 
 
 
 
Fig. 1. Band 4.1 superfamily phylogenetic tree according to (K Takeuchi et al. 1994). 
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Although ERM have some differences in expression pattern, they are considered as 
redundant proteins (Anthony Bretscher, Edwards, and Fehon 2002; Fiévet, Louvard, and 
Arpin 2007). This feature is most likely the precaution of nature against the loss of viable cell 
functions. Thus, in experiments with retinal pigment epithelium cells only the combination 
of antisense RNA for ezrin, radixin and moesin resulted in a pronounced inhibition of cells’ 
adhesion and microvilli formation, whereas knock-out of only one of the proteins showed 
mild changes in the cells’ normal behavior (Kosei Takeuchi et al. 1994). Similarly, knock-out 
experiments in mice showed a strong effect only in those tissues where only one particular 
isoform was expressed. For example, radixin is solely expressed in stereoscilia of hair cells in 
the cochlea (the part of the inner ear), correspondingly, radixin knockdown mice exhibited 
hearing loss. Interestingly, the vestibular stereoscilia did not reveal any distortion, 
apparently because of the small amount of ezrin which is also expressed in vestibular ear 
part (Kitajiri et al. 2004). Unlike ezrin and moesin, radixin interacts with α5 subunit of GABAA 
receptor, therefore, the lack of radixin, in particular, affects GABAA clustering in mice 
hippocampus (Loebrich et al. 2006). Radixin is a dominant ERM protein in hepatocytes, it 
organizes MRP2 (multidrug resistant protein 2) in the bile canalicular membrane and 
attenuation of radixin results in disturbance of bilirubin secretion in bile (Kikuchi et al. 
2002).  
Knock-out of ezrin in mice results in a disarrangement of the brush border structure, 
disrupted microvilli formation and a disarrayed configuration of adhesion complexes in 
intestinal epithelium. Such mice die in neonatal age when they switch to the adult diet 
(Saotome, Curto, and McClatchey 2004). Gastric epithelial (parietal) cells provide acid 
secretion into the stomach, and ezrin mediates the fusion of HCl-containing vesicles with 
the apical part of the cells. In the parietal cells of ezrin deficient mice these vesicles 
accumulate in the cytoplasm, which causes achlorhydria disease (Tamura et al. 2005). 
Furthermore, retinal pigment epithelium cells deficient in ezrin show a reduction in 
microvilli formation that causes defects in photoreceptors (Vera L Bonilha et al. 2006). The 
specificity of ezrin among other ERM was shown by the identification of the phosphorylation 
sites, not present in radixin or moesin, such as Y145 phosphorylated by Src kinase in 
proliferating epithelial cells and by Lck kinase in T lymphocytes (Autero et al. 2003; 
Srivastava et al. 2005). 
 
Moesin knock-out mice showed a normal phenotype, although it is the most distinct in 
sequence protein among ERMs, also differing in some phosphorylation sites (Doi et al. 1999) 
and minor structural features. For example, it reveals stability against calpain in stimulated 
lymphocytes unlikely ezrin and radixin (Shcherbina et al. 1999).  
 
The knock-out studies underscore the role of ezrin as a founder of the group playing a 
crucial role in the normal function of several animal cells types and tissues, as the most 
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profound effect are seen in ezrin knock-out mice, while radixin and moesin mostly play 
redundant roles. Therefore studying ezrin can help to elucidate the functional and structural 
features of the whole ERM group. 
 
 
1.3 Ezrin is involved in cell cortex organization and signaling cascades 
 
Multiple studies of ERM activities in the cells have provided contradictory data. For 
example, in moving T lymphocytes ERM accumulate at the rear end of the cell to mediate 
the retraction process, but in T lymphoma cells phosphorylated form of ERM together with 
ICAM-2 participate in uropod expanding (Charrin & Alcover, 2006; Lee et al., 2004; Helander 
et al., 1996). More precise analysis of different data suggests that the functions and 
regulation of ERM depends on the cell type (Verena Niggli and Rossy 2008) and particular 
developmental stages. This, probably, can be explained by various regulatory factors such as 
interactions between ezrin, radixin, moesin and their binding partners and particular 
signaling ways in different cell types. ERM proteins interact with the number of proteins in 
the cell; in most cases these interactions are mediated via the FERM domain – either 
directly or through intermediate proteins (EBP50, PDZK1). Most FERM domain binding 
partners can be classified as transmembrane proteins (CD43/44, ICAM1/2) and cytosolic 
signalling molecules (phosphatidylinositol 3-kinase, Rho-specific guanine nucleotide 
dissociation Inhibitor GDI) (Anthony Bretscher et al., 2002; Ivetic & Ridley, 2004; Loebrich et 
al., 2006). The high number of the diverse binding partners suggests that ezrin and other 
ERM can be bound to more than one protein at a time, indicating its involvement in complex 
scaffolding and signalling processes. Anyway, all the processes in which ERM participate are 
centered at the cell membrane and related to the regulation of morphology and mechanical 
properties of it. The key processes include arrangement of apical membranes of epithelia, 
such as microvilli assembly and stereocilia formation, participation in parietal cells secretion, 
contribution to immunological synapse function, leucocyte rolling and migration of cancer 
cells, cell division and polarity, junction assembly and Rho GTPase signaling. 
An experiment demonstrating the importance of ezrin in the cell cortex was performed 
on rat fibroblasts transformed with v-fos. Ezrin overexpression and phosphorylation in such 
cells led to pseudopodia formation. Use of micro-scale chromophore-assisted laser 
inactivation (micro-CALI) allowed functional destruction of ezrin precisely in pseudopodia 
and resulted in a complete decomposition of the formations (Lamb et al. 1997). Ezrin is 
responsible for microvilli arrangement in most epithelia (Berryman, Franck, and Bretscher 
1993) and elimination of ezrin leads to disturbance of microvilli formation and, 
consequently, brush borders, the common structure of the apical domain of epithelial cells 
(A Bretscher, 1983;  Bonilha et al., 2006; Saotome et al., 2004). The dependance of microvilli 
formation on ezrin was confirmed in a study of apoptotic events in the cells during which 
microvilli normally disassemble: during this restructurization ezrin and also other ERM 
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proteins were shown to change their membrane localization and undergo 
dephosphorylation in the cytoplasm – the likely reason of microvilli disassembly (J. Chen, 
Cohn, and Mandel 1995). A recent publication demonstrated that repeated cycles of ezrin 
phosphorylation by LOK (lymphocyte oriented kinase) and SLK (STE20-like kinase) allowed 
microvilli in the brush border acting as dynamic, self reorganizing structures (Viswanatha et 
al. 2012). Ezrin, noted to act together with its binding partner NHERF1, was claimed to be a 
key element to regulate and modify the complex system of apical microvilli (Garbett and 
Bretscher 2012). In ezrin -/- intestinal epithelial cells not only the microvilli were short and 
irregular, altogether the cortical web structure was documented to be thicker and 
deformed, as compared to wild type cells, suggesting that ezrin is enlolved in structuring the 
underlying actin apical terminal web, from where microvilli emerge (Saotome, Curto, and 
McClatchey 2004). A specific form of epithelial microvilli is found in the retinal pigment 
epithelium, which expresses only ezrin, but not other ERM. Its highly specialized cells have 
very long microvilli which supply photoreceptors with nutrients (Bok 1993). The knock-down 
of ezrin in this cell line leads to a great decrease in the number and length of microvilli; ezrin 
disregulation in these cells has been suggested as a reason of  retinal degenerations (Kivelä 
et al. 2000). Moreover, moesin and radixin overexpression experiments fail to compensate 
for the lack of ezrin in retinal pigment epitelium (Vera Lúcia Bonilha, Finnemann, and 
Rodriguez-Boulan 1999). This phenomenon of selective usage of a particular ERM protein in 
some cells' types implies the mechanisms that orchestrate the circulation of ERM proteins 
remain ambiguous. 
 
As a linker between membrane and cytoskeleton, ezrin is an important member in the 
complexes of cell-cell adhesion and cell-surface contact. In MTD-1A cells, attenuation of 
ERM expression caused abnormality in the formation of these complexes (K Takeuchi et al. 
1994). In particular, knock-down of all ERM together caused cells to deattach from the 
plate; single protein knock-down showed that cells continue to grow normally but failed to 
reattach after trypsinizationg in case of ezrin or radixin, but not moesin knock-down. In 
mamalian epithelial cells overexpressing the T567D mutant of ezrin, mimicking the protein 
active form, led to inability of cysts formation in a collagen matrix, which was caused by 
disrupting and preventing the formation of cell-cell junctions (Monique Arpin et al. 2011). 
Stimulation of epithelial cells with HGF (hepathocyte growth factor) similarly led to 
dissociation of cell-cell junctions following phosphorylation of tyrosine 477 in ezrin and to 
relocalization of ezrin to the front membrane of migrating cells (Naba et al. 2008). Processes 
involved in establishing cell contacts depend on activation-deactivation cycles of Rho and 
Rac GTPases (D’Angelo et al., 2007, Hatzoglou et al., 2007). ERM can be found as 
participants in GTPase cascades, for example, in A431 EGF-stimulated cells, ezrin interacts 
with PLEKHG6 (Rho guanine nucleotide exchange factor) that activates RhoG and the RhoG 
effector ELMA, showing the ezrin ability to regulate upstream and downstream effectors in 
Rho-cascades (D’Angelo et al., 2007; Ivetic & Ridley, 2004).  
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Ezrin participates in assocition of T cells and antigen presenting cells (APC) during 
immune responce: after activation of T cell receptor (TCR) ezrin accumulates together with 
CD43 at the perifery of the immunological synapse (IS), facilitating contact between the two 
cells; the relocation of ezrin to the perifery coincides with actin polimerization at the distal 
parts of the IS (Cullinan, Sperling, and Burkhardt 2002; Roumier et al. 2001). The relocation 
of ezrin requires its dephosphorylation-rephosphorylation which might be ensured via some 
Rho-GTPase regulation. The reported interaction of ezrin with Rho-GDI at the IS supports 
this hypothesis (Delon, Kaibuchi, and Germain 2001). At the IS perifery ezrin recruits the TCR 
to the T cell-APC contact area arranging the clustering of the receptors that is required for 
the maturation of immunological synapses (Grakoui et al. 1999).  
The role of ezrin during leucocytes rolling is linked to microvilli formation which ensures 
thethering of leucocytes to blood vessels endothelium. The process requires interaction of 
PSGL-1 (P-selectin glycoprotein ligand-1) on leucocyte membrane with P-selectin on the 
membrane of endotelial cells and is mediated by binding of ERM to PSGL-1. Disruption of 
ezrin/PSGL-1 complex results in unstable microvilli in leucocytes (Spertini, Baïsse, and 
Spertini 2012). Microvilli retraction allows cell rolling and ezrin phosphorylation-
dephosphorylation cycles are required for this event (Ivetic and Ridley 2004). The regulation 
of ezrin phosphorylation in this process is thought to be conducted by Rho-kinases (Oshiro, 
Fukata, and Kaibuchi 1998).  
 
Ezrin also performs an important role in dividing cells. In mammalian colonic epithelial 
cells (Caco2), grown in matrigel, ezrin undergoes spacial redistribution during the mitotic 
cycle (Hebert et al. 2012). From equal cortical distribution in G1-phase, in S-phase ezrin 
changes to uni-polar distribution arranging one of the centrosome, thereby setting the 
spindle orientation; in telophase ezrin concentrates in the cleavage furrow (Hebert et al. 
2012). In eight-cell mouse embryos ezrin relocates from junctions to epical parts of the cells, 
which on one hand allows them to divide and form the developing embryo and also to 
establish mitotic spindle orientation (Louvet et al. 1996). Similar observations of ezrin 
relocation were made during development of the outer layer in mouse blastocysts (Louvet 
et al. 1996). ERM-1 also undergoes a redistribution from junctions to apical parts of the cells 
during initial tissue differentiation in C.elegance embryo (Van Fürden et al. 2004). This 
function in polarity establishment was also observed during formation of lumina in 
intestines, in particular, during arranging of the apical junctions. Apical junctions ensure 
normal development of lumina by coordinating the cells division. In ezrin deficient intestinal 
cells the lumina was deformed and the apical junctions had abnormal elongated shape 
(Saotome, Curto, and McClatchey 2004).  
 
The previous examples demonstrate that ERM proteins and ezrin, in particular, are major 
components in cell adhesion and mobility, also being involved in Rho-cascades. These 
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features obviuosly makes them important participants in cancer cells migration. Ezrin 
distribution in the cell can be characteristic for some type of cancers. Thus, in breast cancer 
metastases ezrin favours the cytoplasmic localization or accumulates at membrane in non-
polarized way, whilst in normal breast epithelium and in non-malignant breast tumor ezrin 
localization is apical (Monique Arpin et al. 2011). These data are in agreement with a recent 
study (Hoskin et al., 2015), which suggested that ezrin has more influence on metastatic 
development rather than on primary breast cancer, mostly by regulating focal adhesions 
and invadopodia dynamics in processes controlled by Rho GTPases. It was also shown that 
ezrin is involved in metastasis formation in osteosarcoma and its knock-down in 
osteosarcoma cell lines leads to reduced cell growth (Lo Vasco et al. 2013); ezrin silencing in 
mice with osteosarcoma decreased its dissemination (Khanna et al. 2004). The possible 
regulatory mechanism can involve phosphoinositide-specific phospholipase PI-PLC, wich 
regulates the concentration of  PIP2, an ERM activator, and is colocolized with ezrin in 
osteosacroma cell line (Lo Vasco et al. 2013). In EGF stimulated HeLa cells ezrin was shown 
to increase cells invasion properties, probably due to activation of PI3-kinase and SK2 
(sphingosine kinase) via MAPK-pathway (Adada et al. 2015). Although, the mechanisms of 
ezrin participation in cancer progression revealed up to date are dependent on the cancer 
type in animal models and the way of stimulation in cell lines, the fact that the cancerogenic 
function of ezrin is based on remodelling of cell membrane morphology and requires the 
active state of the protein is commonly accepted. 
 
 
1.4 Dormant and activated states of ezrin 
 
In the cell ezrin undergoes a switch between the active and dormant state. The dormant 
state is charachterized by an autoinhibitory interaction between N-ERMAD and C-ERMAD 
(Gary and Bretscher 1995) that can be disrupted by interaction of ezrin with membrane PIP2 
(phosphatydilinositol 4,5-bisphosphate) and phosphorylation of the conserved threonine 
567 (Verena Niggli and Rossy 2008). In radixin and moesin, these are threonine 564 and 
threonine 558, respectively (Matsui et al. 1998). The sequences around these threonines are 
preserved to such extent that phosphorylated threonine can be recognized in all three ERM 
proteins by the same antibodies generated against only one phosphorylated ERM protein 
(Matsui et al. 1998).  
Although both, PIP2-binding and threonine phosphorylation, are aknowledged as factors 
modulating ezrin behaviour in the cell, different models on ezrin activation excist: 1) only 
PIP2 binding at the cell membrane is crucial during the process (Shigenobu Yonemura et al. 
2002), 2) phosphorylation of C-terminal threonine is the key event during activation (Matsui 
et al. 1998; Simons et al. 1998), 3) initial PIP2 binding, then stabilizing threonine 567 
phosphorylation are required for full activation (Hughes & Fehon, 2007; Niggli & Rossy, 
2008). To elucidate the question, researchers use different well established means, such as, 
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mutants analysis, binding to artificial lipid structures decorated with PIP2 lipids, binding 
assays using interaction partners. Mutants analysis includes binding sites deletions or their 
modifications, as well as mutants at the C-terminal threonine: phosphomimicking mutants, 
ezrin T567D or T567E that imitates partly activated protein due to introducing by aspartic 
acid or glutamic acid as negative charge similar to the phosphate group; un-phosphorylable 
mutant ezrin T567A that cannot be modified by kinases in the cells and is concidered as 
constituitively inactive form.  
As phosphatidylinositol-4,5-bisphosphate and specific phosphorylation have a critical 
effect on ezrin function, it is useful, firstly, to review the role of these two factor in general 
in the cell. 
 
1.4.1 Role of PIP2 in the cell 
 
Phosphotidylinositol 4,5-bisphosphate PIP2 is well known as important bioregulator in the 
cell. Its cleavage results in release of phosphotidylinositol, IP3, which increases Ca2+ 
concentration in the cell, and diacylglycerol DAG, which regulates phospholipase C activity. 
PIP2 is incorporated in the plasma membrane of the cell and comprises 1% of all 
phospholipids (Gillooly and Stenmark 2001) and 99% of those with two phosphate groups 
(Vanhaesebroeck et al. 2001). PIP2 acts as the second messenger in many processes 
including membrane trafficking, enzyme activation, membrane-cytoskeleton connection, 
microvilli formation. The multitude and diversity of its functions can be explained by the 
existance of the different PIP2 pools in the membrane (Martin 2001; Simonsen et al. 2001). 
It is not yet clear what regulates PIP2 clustering, although some works showed that PIP2 
accumulates in cholesterol rafts (D. A. Brown and London 2000) and that MARKCS protein 
can sequester PIP2 in the membrane using electrostatical forces and, therefore, does not 
perturb its interaction with other molecules, like PH domain of PLCδ (McLaughlin et al. 
2002). The important role in PIP2 sequestering was recently ascribed to Annexin A2 which 
was shown to induce PIP2 clusters formation in Ca2+-dependet manner, moreover the 
complex with S100A10 protein was suggested to increase the properties of Annexin A2 to 
organize the lipid rafts (Drucker et al. 2013). The distinctive physical feature of PIP2 is its 
negative charge provided by the phosphate groups and, depending on pH and binding 
partners can be -3, -4 and -5. This feature of PIP2 and other phospholipids makes the plasma 
membrane the most negatively charged comparment of the cell (its electric field equals to 
105 V/cm) and enables electrostatic interactions with many proteins (Goldenberg and 
Steinberg 2010). For example, 37 proteins were identified within the Rho, Ras, Arf and Arb 
families of small GTPases that electrostatically interact with cell membrane PIP2 (Shi et al. 
2013). Another characteristic of PIP2 is its big head group that allows protruding in the 
aqueous phase further than other phospholipids of the plasma membrane (Fig. 2). 
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Fig. 2. Comparing schematical structures of POPC, cholesterol and PIP2. A – chemical structures, B – molecular models. 
POPC (1-palmitoyl-2-oleoyl-3-phosphatidylcholine) is the most common phospholipid in the cells. Figure is taken from 
publication (McLaughlin et al. 2002). 
 
 
 
There are several known protein domains that specifically bind PIP2, among them the PH 
domain (PLC-δ), ENTH domain (CALM protein), FERM domain and the PX domain (NADPH 
oxidase, PI3-kinase). The presence of basic and/or aromatic amino acids is important for the 
binding to negatively-charged PIP2, as well a conformational factor, providing a binding 
“pocket” with hydrogen-bonds (Prehoda et al. 2000).  
 
The interactions with FERM domains of ERM proteins, as well as with α-actinin, spectrin, 
and vinculin (Czech 2000), indicated that PIP2 is one of the essential regulators of 
cytoskeleton assembly during microvilli and membrane raft formation and cell adhesion. A 
charachteristic experiment employing laser tweezers showed that a change in PIP2 
concentration is a sensitive tool to adjust the strength of membrane/cytoskeleton 
interactions, i.e., higher PIP2 concentration in the membrane corresponds to a higher 
adhesion energy of ezrin/actin interaction (Raucher et al. 2000). Similar findings were 
obtained by analysing with AFM technique MDCK cells injected with PIP2 : the membrane 
tension increased by 50% after the injection. At the same time ezrin deficient cells with 
unchanged PIP2 levels showed a 40% drop in the membrane rigidity, too (Braunger et al. 
2014). Enrichemt of PIP2 in membrane ruffles was detected in EGF stimulated HeLa cells and 
in NIH-3T3 fibroblasts (Honda et al. 1999; Tall et al. 2000). High concentrations of PIP2 in the 
membrane can induce activation of PIP kinases, which are responsible for the synthesis of 
different phosphatidylinositols (Czech 2000). Up-regulation of phosphatidylinositol 4-
phosphate 5-kinase, resulting in PIP2 synthesis, recruited ezrin to the membrane in HeLa 
cells and mouse fibroblasts (Auvinen, Kivi, & Vaheri, 2007; Matsui, Yonemura, & Tsukita, 
INTRODUCTION 
 
10 
 
1999). In contrast, phospholipase C inactivated ezrin via decreasing PIP2 levels in the 
membrane (Hao et al. 2009).  
 
Not all PIP2 binding domains have strong affinity to this phospholipid: sometimes the 
result of the interaction is only anchoring of multidomain proteins or protein complexes to 
the membrane and requires further membrane interaction for stabilization. For example, 
WASP proteins become active only when they bind to membrane PIP2 and Cdc42 at the 
same time (F. Chen et al. 2000) and dynamin can stably bind to membrane only in all 
oligomeric form when its several PH domains bind several neighbouring PIP2 molecules 
(Lemmon and Ferguson 2000). This aspect of different modes of PIP2/proteins interaction is 
interesting in respect to this study, too, as the feature of PIP2/ezrin binding is one of the 
phenomenons questioned here. In this regard it is important to recall that ezrin was shown 
to accumulate in membrane ruffles and microvilli, following the PIP2 distribution (A 
Bretscher, 1983; A Bretscher, Reczek, & Berryman, 1997; Menager, Vassy, Doliger, Legrand, 
& Karniguian, 1999).  
 
1.4.2 Protein phosphorylation as one of the main regulators of cell functioning 
 
The attention to the importance of enzymatic phosphorylation of proteins in the cells 
arose in 1950s by Fischer and Krebs, who first demonstrated that enzyme activity can be 
regulated by reversible phosphorylation (FISCHER and KREBS 1955). The specific features of 
the phosphate group are dianionic nature (not inherent for any amino acids) and the ability 
of phosphoryl oxygens to form hydrogen bonds (Louise N Johnson 2009), therefore the 
addition of negatively charged phosphate group induces subsequent conformational 
changes in proteins. Tyrosine, threonine and serine are the most common phosphorylated 
amino acids; in different species in homologous proteins they can be substituted by 
negatively charged aspartic or glutamic acids. In modern research proteins with 
phosphorylated amino acids are commonly substituted with mutants bearing aspartic or 
glutamic acids instead of the original phosphorylatable residue.    
The phenomenon of enzymatic phosphorylation had appeared early in the evolution of 
life and phosphorylation of specific residues is important for both eukaryotic and bacterial 
cells. For example, CheY, a bacterial chemotaxis protein, transits to the active conformation 
due to electrostatic repulsion caused by phosphorylation (L N Johnson and Barford 1993). 
Eukaryotic phosphorylation can lead to association of proteins, like in STAT (signal 
transducer and activator of transcription), but also to protein dissociations as in case of 
serine and threonine phosphorylation in the complex between pRb (retinoblastoma protein) 
and transcription factors E2F/DP1 (X. Chen et al. 1998; Rubin et al. 2005). Phosphorylation-
dephosphorylation events modulate MARCKS membrane attachment/reattachment modes, 
together with PIP2 that mediates correct protein targeting to the membrane (Kim et al. 
1994). The modification of proteins with phosphate group influences such processes as 
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protein transport within the cell, ability to interact with other cell components, marking 
proteins as targets for degradation. Monitoring phosphorylation of particular proteins can 
help in disease diagnosis (Cohen 2001).    
 
There are many known examples of how addition of phosphate group influences proteins 
and enzymes states, but, as evolution studies show that the genes of kinases became 
diverse even between different species, the conservation of phosphorylation sites in 
proteins between species is not too common (Louise N Johnson 2009). Therefore to 
understand a particular process, in the case of this thesis – ezrin activation by 
phosphorylation, the specific protein structure has to be taken into consideration.  
 
 
1.4.3 Structure and conformations of ezrin 
 
As already mentioned, the ezrin molecule is composed of the highly conserved N-
terminal FERM domain, also known as N-ERMAD, the central α-helical domain, and C-
ERMAD. N-ERMAD of human ezrin consists of 297 amino acids (Smith et al. 2003) and is 
subdivided into 3 lobes, F1, F2 and F3 that are shaped in a clove-like manner and contain 
the PIP2-binding site and binding sites for membrane proteins. The crystal structure of full 
length ezrin is not yet available, but the N-ERMAD structures of all three ERM have been 
solved: each lobe has a certain structure, i.e. F1 (2-82 amino acids) maintains a ubiquitin-like 
folding, F2 (83-195 amino acids) shows structural characteristic of acyl-CoA-binding 
proteins, F3 (196-297 amino acids) is similar to a PH (pleckstrin homology) domain (Smith et 
al. 2003). N-ERMAD of radixin has the following dimensions, according to its crystalized form 
(K Hamada et al. 2000): the surface projection equals to 70*70 Å, the height is 40 Å. 
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Fig. 3. Models of intra-molecular interaction of N-ERMAD with C-ERMAD of insect moesin (Spodoptera frugiperda). C-
ERMAD is depicted in red, F1, F2, F3 domains of N-ERMAD are in blue color, central α-helical domains is in yellow. The right 
figure depicts the contact zones of α-helical domain. Taken from Fehon, McClatchey, and Bretscher 2010; Li et al. 2007.  
 
 
 
The PIP2 binding site was identified in the N-ERMAD, using different generated mutants, 
and most likely comprises regions between the F1 and the F3 lobes: residues 12-115 and 
233-310. The characteristic feature of this regions are sequences KK(X)nK or KK(X)nRK, i.e. 
basic amino acids sequences, where X - any amino acid (Barret, Roy, Montcourrier, 
Mangeat, & Niggli, 2000; Hamada, Shimizu, Matsui, Tsukita, & Hakoshima, 2000). The most 
important residues are thought to be the lysines 253, 254, 262, 263, and also 63 and 64; the 
simultaneous mutation of all of these lysines led to substantial decrease in binding to PIP2–
containing liposomes (Barret et al. 2000). The study of the crystalized radixin complex with 
inositol triphosphate IP3 confirmed the presence of basic amino acids in the area of contact 
with IP3/PIP2 head and suggested that phosphate groups might imply pressure on the F3 
lobe to complete binding. This in turn pushes the C-terminal part and therefore mediates 
unmasking of N-ERMAD (Keisuke Hamada et al., 2003; K Hamada et al., 2000). Because 
there are no evidences that IP3 can activate any of ERM proteins, the structures with IP3 
should be considered with caution. 
N-ERMAD has strong binding activity towards C-ERMAD that consists of a β-strand and 
four α-helices (A-D), C-ERMAD bears a conserved actin binding site. The C-N association of 
ezrin was shown in FRET studies with the use of YFP-ezrin-CFP construct expressed in HeLa 
cells (Zhu, Liu, and Forte 2005). The crystal structure of the moesin N-ERMAD/C-ERMAD 
complex (Pearson et al. 2000) revealed that in the inactive state of the protein, the A and D 
helices of the C-ERMAD stretch along the F2 and F3 N-terminal lobes and cover their binding 
sites. The particular residues that might contribute to this intra-molecular interaction were 
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identified by comparison of the crystal structures of the sole N-ERMAD, i.e. the active state, 
and the inactive N-ERMAD/C-ERMAD complex (Fig. 3, 4). These residues are 135–150 and 
155–180 in the F2 subdomain and 210–214 and 235–267 in the F3 subdomain (Smith et al. 
2003). It was noticed that the degree of disorder (characterized by B factor which is the 
measure of relative vibrational motion of different protein structures) of the F2 and F3 lobes 
in crystalized N-ERMAD is higher as compared to that in N-ERMAD bound to C-ERMAD 
(inactive state), suggesting that these subdomains are mobile structures and require C-
ERMAD or other proteins to stabilize their conformation. It is also higher than the B factor of 
the F1 lobe alone (Smith et al. 2003). Such conformational mode was named keystone 
interaction, i.e. the mode of binding between several proteins or domains to stabilize the 
existing connection. Indeed, the ezrin binding partner EBP50 was shown to interact with 
moesin N-ERMAD in the way to mimic the D-helix interaction with F3 in the N-terminal part 
of ezrin, particularly interacting with residues 210, 212, 214 and 244 (Finnerty et al. 2004). 
Similarly, ICAM-2 binds to the F3 lobe interacting with amino acids 260, 281, 285, 288 (K 
Hamada et al. 2000). ERM mutants in the hydrophobic region of the D helix fail to mask N-
ERMAD interaction sites (Gary and Bretscher 1995). The actin binding site (ABS) that is 
contained in the last 30 amino acids of C-ERMAD (Anthony Bretscher, Edwards, and Fehon 
2002) is also masked in the N-ERMAD/C-ERMAD complex. ABS of ezrin has a conservative 
sequence: it has 30% similarity, for example, to glycophorin, another member of the band 
4.1 protein family that connects membrane proteins and actin filaments (Gould et al., 1989; 
Algrain et al., 1993;  Chishti et al., 1998); it includes the amino acid region KYKXL that is also 
found in other actin binding proteins, for example, in myosin heavy chain (Turunen, 
Wahlström, and Vaheri 1994). The X is represented in ERM proteins by the threonine and its 
phosphorylation does not affect the binding efficiency of recombinant radixin C-terminal to 
actin (Matsui et al. 1998), underscoring the exclusive conformational role of the residue. 
Some studies suggest that PIP2 binding to N-ERMAD of ezrin can unmask the threonine 
567 in the C-terminal to allow its phosphorylation (Fievet et al. 2004). Phosphorylation, in 
turn, brings the whole protein to a less folded conformation. A number of kinases were 
reported to phosphorylate this residue, including Rho kinase, SLK family, PKCθ (Monique 
Arpin et al. 2011). According to the crystal structure of inactive moesin the C-terminal 
threonine is placed in between bound N-ERMAD and C-ERMAD, therefore introducing a 
negative phosphate group at this threonine induces electrostatic and steric changes which 
weaken the bond between the C- and N-terminal domains (Pearson et al., 2000; Matsui et 
al., 1998; Nakamura et al., 1999). 
 
The α-helical domain has the structure of a coiled-coil and can be subdivided into 3 
helices: αA, αB and αC. It is the least studied part of the ERM molecule but when the crystal 
structure of full length moesin from Spodoptera frugiperda was solved (Li et al. 2007), its 
role in N-ERMAD masking and, in particular, masking of the PIP2-binding site was unraveled. 
The analysis of the structure revealed several interaction sites of the α-helical domain with 
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the F1 and F2 lobes of moesin N-ERMAD (Fig. 3), especially important for these interactions 
are the 70 Å anti-parallel coiled-coil region on the border between the αB and αC helices 
which contains a heptad repeat, a characteristic feature of all coiled-coils. This coiled-coil 
region relaxes its condense structure during the activation process (Li et al. 2007). The 
biochemical experiments and sequence comparison with the other ERM proteins and merlin 
showed that the loop between the αB and αC helices interacts with N-ERMAD and the 
interaction sites are conserved sequences within the ERM family (Hoeflich et al., 2003;  
Edwards & Keep, 2001). Interestingly, limited enzymatic digestion of inactive monomers and 
homodimers of ezrin yielded different proteolysis patterns (A Bretscher, Gary, and 
Berryman 1995). A possible explanation is the formation of the heptad repeat that occurs 
not only within the coiled-coil of one ezrin molecule but also between two helices of 
different ezrin molecules in the case when ezrin is the dimer. Moreover, it was noticed that 
stimulation of the HeLa and gastric parietal cells with histamine resulted in the increased 
monomeric pull of ezrin and decreased fraction of the oligomeric protein form, suggesting 
that inactive ezrin is  represented mostly by dimers and oligomers while active ezrin form is 
monomeric (Zhu, Liu, and Forte 2005).  
 
 
 
 
 
Fig. 4. Schematic structure of an ERM molecule. Illustration source (Ben-Aissa et al. 2012). 
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It is thought, in general, five interacting sites between N-ERMAD and C-ERMAD support 
the closed conformation of ERM proteins, also three sites are exist in the α-helical domain 
folding around N-ERMAD and also masking N-ERMAD binding sites (Pearson et al., 2000; Li 
et al., 2007). The multitude of masking structures suggests flexibility and sensitivity in the 
regulation of ezrin functions. Little known about mechanisms of ERM interaction with their 
binding partners, but many of those have been identified. Interaction studies with 
unphosphorylatable ezrin T567A, ezrin-wt, phosphomimicking ezrin T567E and the N-
ERMAD part expressed in Jeg-3 cells (Viswanatha et al. 2013) revealed that every 
represented form of the ezrin molecule has its own prefered binding partners. For example, 
proteins FHOD1 (formin-diaphanous family), SCYL3 (Ezrin-Binding protein PACE-1) bind to 
ezrin T567A as efficiently as to ezrin-wt; about 50% of ezrin-wt was phosphorylated in the 
cells, therefore it was considered as active or partially active form while ezrin T567A 
represents the inactive state of the protein. DAG1 and EBP50, in turn, bind more efficiently 
to ezrin T567D, considered the fully open form by Viswanatha, and still better to N-ERMAD 
which lacks the C-terminal part and, therefore, has all its binding sites fully accessible. This 
finding supports the theory that ezrin may adopt at least three conformational states, each 
performing certain functions in the cell, and confirms that the C-terminal part of ezrin 
indeed prevents some protein interactions even in the fully opened ezrin T567E mutant. 
Most of the binding partners of ezrin interact with regions located within N-ERMAD 
(CD43/44, ICAM1/2, Dlg1, NHE1/3, Ras, S100P, ect.), some with the coil-coiled structure of 
the α-helical domain (Fes, Eps8, WWOX), and only few with the C-ERMAD (CLIC3, SCYL3, 
actin) (Viswanatha et al. 2013). Of course, the strongest binding partner of inactive ezrin is 
PIP2 (V Niggli et al. 1995). 
  
Well analyzed binding partners of ezrin, CD43/44 and ICAM 1/2, can unveil some details 
of the binding mechanism. These proteins interact with N-ERMAD via their cytoplasmic 
domains. No certain binding sequences were yet identified within these proteins, but some 
rules seem to exist, i.e. these cytoplasmic tails are rich in basic residues, and the interaction 
mode depends on ionic strength and is favored by the acidic environment within the 
interaction area. Therefore, the cleft between lobes F2 and F3 in the N-terminal domain, 
which is rich in glutamate and aspartate, could constitute a preferable interaction site (K 
Hamada et al., 2000; S Yonemura et al., 1998). Other proteins that interact with FERM-like 
domains are also characterized by positively charged residues and fit in the acidic groove 
between the F2 and F3 lobes. For example, kinesin-like-protein KIF1C interacts with the 
FERM domain of tyrosine phosphatase PTP-D1 (Dorner et al. 1998), CD44 binds band 4.1 
protein (Nunomura et al. 1997), and the α-interferon receptor 1 subunit interacts with the 
FERM-like domain of JAK kinase (Yan et al. 1996). These findings infer the universal nature 
of the binding model of ERM and band 4.1 superfamily proteins with their membrane 
interacting partners. 
 
INTRODUCTION 
 
16 
 
1.5 Ezrin activation hypothesis   
 
All existing studies are in agreement that ezrin’s activation is essential for its functioning 
in the cell and that the activation of the protein is facilitated by certain factors: PIP2 binding 
and C-terminal threonine phosphorylation, but the effect and contribution of each of these 
events are not fully understood. In the dormant, “closed” conformation ezrin and other 
ERM proteins reside in cytoplasm and their protein binding sites and actin binding site are 
masked. Transition to the activated state, according to the most widely accepted hypothesis 
is mediated, first, by binding to PIP2 in the plasma membrane at ERM’s conserved PIP2-
binding site. This subsequently unmasks the C-terminal threonine (T567 in ezrin) and allows 
its phosphorylation by Rho-kinase, protein kinase C (Hughes & Fehon, 2007; Niggli & Rossy, 
2008) and some other kinases. Activated ezrin is localized at the membrane, especially in 
actin rich membrane structures, and able to bind to cytoplasmic tails of membrane proteins 
via its N-ERMAD and to actin filaments via its C-terminal actin binding site (Nakamura et al., 
1999; Matsui et al., 1998; Huang, Wong, Lin, & Furthmayr, 1999; Pearson et al., 2000). First 
experiments in this direction showed that the PIP2-binding mutant, generated by mutation 
of lysines in PIP2-binding sites, showed impaired PIP2 binding in vitro. In vivo this ezrin 
mutant failed to localize at the membrane and showed a diffuse cytoplasmic distribution 
(Barret et al. 2000). Liposome binding experiments demonstrated that ezrin binds 
specifically to PIP2 incorporated in POPC liposomes (Herrig et al., 2006; Blin et al., 2008), and 
in combination with an actin filaments binding assay revealed that moesin binds F-actin in 
presence of PIP2 but not in presence of phosphatidylinositol PI (Huang et al. 1999). More 
works demonstrated that PIP2 can also modulate the binding behavior of ERM proteins. For 
example, in vitro binding studies showed that the binding of moesin to CD44, a known 
interaction partner of ERMs, was possible only in presence of PIP2 (K Hamada et al. 2000). 
Analysis of ezrin binding to PIP2-containing solid supported lipid bilayers (SSLB) by quartz 
crystal microbalance (QCM) and fluorescence microscopy suggested that the binding occurs 
in cooperative manner resulting in ezrin accumulation in distinct patches on the surface 
(Herrig et al. 2006; Bosk et al. 2011). Probably PIP2 not only attaches ezrin to the membrane 
and introduces changes in its conformation but also is involved in localizing the protein 
along the membrane in an ordered manner. These findings promote the idea of PIP2 as the 
main factor of ERM activation and phosphorylation as a facultative event.  
For further discussion it is important to note that it was shown in activation studies with 
ezrin, radixin and moesin that they behave similarly (Shigenobu Yonemura et al. 2002), 
therefore findings about other members of ERM group can be attributed to ezrin too. 
There are evidences that overexpression of phosphomimicking mutants of ezrin (T567D) 
and moesin (T558D) can increase the ERM fraction bound to the membrane and induce 
formation of microvilli and lamellipodia (Hao et al. 2009; Oshiro et al., 1998; S Yonemura & 
Tsukita, 1999; Gautreau, Louvard, & Arpin, 2000). Overexpression of the phosphomimicking 
mutant in HTB-58 cells increased their spontaneous migration (Austermann et al. 2008). 
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Phosphorylated at the C-terminal moesin, purified from platelets, was shown to bind F-actin 
filaments in co-sedimentation assay more efficient than non-phosphorylated protein 
(Nakamura et al. 1999). Such findings promoted the idea that PIP2 binding is only optional 
for activation or specifically involved in certain processes. Several kinases can phosphorylate 
the conserved C-terminal threonine of ERMs: protein kinase C α and θ, Rho-kinase, Nck-
interactin kinase (NIK) were reported to bind ezrin (Fiévet et al., 2007; Ivetic & Ridley, 2004; 
Baumgartner et al., 2006), as well as mentioned before (LOK (Simons et al. 1998) and SLK 
kinases (McClatchey 2014). Existence of the enzyme diversity means that, depending on cell 
type and the cell process, different pathways can activate ezrin, and probably also radixin, 
moesin.  
Several other residues in ezrin can be phosphorylated, for example, tyrosine 477 can be 
phosphorylated by Src kinase (Heiska and Carpén 2005). Although this residue does not 
contribute to the activation process it is thought to participate in signal transduction; also 
tyrosine 477 phosphorylation site is not present in other ERM (Monique Arpin et al. 2011). 
The conserved tyrosine 145 is phosphorylated downstream of EGF stimulation of epidermal 
cells (Krieg and Hunter 1992), and in T lymphocytes this tyrosine is the substrate for kinases 
of the Src family (Autero et al. 2003). Tyrosine kinases activation can also lead to the 
formation of homotypic and heterotypic (between members of ERM family) oligomers in the 
cells (Shcherbina et al. 1999). Although the function of these oligomers is not clear yet, their 
formation might be a tool to modulate and structure the cell cortex.  
It is important to mention that regulation of ERM activity can be modulated by 
phosphatases, thus, protein phosphatase 2C and myosine phosphatase are known to 
dephosphorylate ezrin in vitro (M. J. Brown et al. 2003) (Parameswaran, Matsui, and Gupta 
2011). Based on this knowledge, the C-terminal threonine phosphorylation seems to be an 
important factor regulating ERM behavior. 
 
Biophysical studies were also employed to clarify the ezrin activation theory and they 
revealed that synergystic actions of the known activating factors might occur. For example, 
another F-actin binding assay employing His-tagged ezrin, bound to supported membranes 
either via PIP2 or via DOGS-Ni-NTA, showed that ezrin interacts with actin when it is bound 
to PIP2–containing membranes, but not when it is bound via the His-tag to DOGS-Ni-NTA 
lipids incorporated in the lipid bilayer (Janke et al. 2008). The scheme of the experiments is 
depicted on Fig. 5A. Hao et al. (Hao et al., 2009) in their experiments with 
phosphomimicking moesin T558D showed that either mutation in PIP2-binding site or 
depletion of PIP2 by neomycin caused inability of moesin to localize at the membrane. 
Further experiments with different ezrin constructs expressed in epithelial cells revealed 
that a function of PIP2 is not only in accumulating ERM at the membrane but also its binding 
is required for threonine phosphorylation: when ezrin was anchored to the membrane via a 
fused PH domain it could not undergo C-terminal threonine phosphorylation if the PIP2-
binding site was defective. In contrast, ezrin-wt, also fused to a PH domain, could be 
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phosphorylated at the membrane as it was detected with antibodies against T567 
phosphorylated ERM (Fievet et al. 2004).  
 
 
A 
 
 
 
 
B 
 
Fig. 5. Scheme of experiments. A – The model employed in the work of Janke et al. in the actin binding 
experiments. Ezrin was bound to (c) PIP2- or (d) DOGS-Ni-NTA-containing SSLB, actin filaments were attached to the 
cantilever of AFM. In the situation (c) ezrin was partially activated by the interaction with PIP2 and was capable of actin 
binding. Figure was adapted from Janke et al. 2008. B – The model used in this thesis. Fluorescently labeled ezrin 
molecule is thought to be in the closed conformation when bound to DOGS-Ni-NTA-containing SSLB, therefore 
FRET is expected to occur. In the case of ezrin bound to PIP2-containing SSLB the conformational changes occur 
and FRET could not be possible anymore. The figure from  Fehon, McClatchey, and Bretscher 2010 was used for this 
scheme. 
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A third activation factor of ezrin is known and by now it is the less studied one. S100P 
was identified as an ezrin binding protein and shown to facilitate actin binding of ezrin 
(Koltzscher et al. 2003). S100P binds to the N-ERMAD (82-173 residues) in Ca2+ dependent 
manner and competes with PIP2 in ezrin binding in vitro (Austermann et al. 2008). Co-
localization with ezrin at the membrane together with the evidences of overexpression of 
both, ezrin and S100P, in cancer cells (Austermann et al., 2008; Curto & McClatchey, 2004; 
Diederichs et al., 2004) suggest the participation of the two proteins in metastatic events. 
 
Two recent studies in the field of ezrin activation developed new experimental system for 
biochemical and biophysical analysis of the protein, which presented evidence supporting a 
synergystic mode in the ezrin activation process. Interactions in a three component system 
“membrane–ezrin–actin” were investigated in vitro. Experiments using ezrin in the system 
similar to described in Fig. 5A showed differences in actin binding to ezrin and its threonine-
mutants (Bosk et al. 2011). Ezrin doped membranes of the two types were incubated with 
actin filaments and the actin binding of ezrin wild type protein was compared to the binding 
of its mutants, ezrin T567A and ezrin T567D. The ezrin-actin binding was then analyzed by 
fluorescent microscopy detecting signal of fluorescently labeled F-actin. The most efficient 
interaction with F-actin was seen for the phosphomimicking ezrin T567D bound to PIP2-
containing membranes, the least efficient for the un-phosphorylatable ezrin T567A. Ezrin-wt 
and ezrin T567D anchored to the membrane via His-tag show similar intermediate actin 
binding. In contrast, PIP2 binding strikingly enhanced the interaction with actin for both of 
them. This first in vitro F-actin/ezrin/membrane interaction thus showed that ezrin 
activation, characterized here by efficiency of actin binding, was dependent strongly on PIP2, 
and threonine 567 phosphorylation was suggested as a secondary process which stabilizes 
the connection between ezrin and the membrane. Later, more detailed findings were 
obtained by the same group with the use of colloidal probe microscopy in a similar 
experimental system with ezrin attached to the two types of lipid bilayers. Measured by 
AFM binding forces between ezrin and F-actin revealed that a singular ezrin-actin bond has 
the same characteristics in all the experimental conditions, but the cumulative binding is 
much stronger for the protein bound to the membrane via its PIP2-binding site than via the 
His-tag. Moreover only a slight increase in cumulative binding force for the T567D mutant 
was observed as compared to ezrin-wt (Braunger et al. 2014). These works unraveled 
important details about conditions of the ezrin activation and its binding to F-actin, showing 
the characteristics of the singular bond and confirming the synergism of the activation 
factors. But the question, whether phopshoprylation has only a minor influence in the 
process, is still not answered clearly.  
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1.6  Aim of the study and general experimental approach 
 
The aim of this work was to directly reveal conformational changes associated with ezrin 
activation with the use of in vitro system and purified proteins. The demonstration of the N-
ERMAD–C-ERMAD complex dissociation upon action of the activating factors will be the first 
experiment of such type in the field of ezrin studies. Förster Resonance Energy Transfer 
(FRET) technique was chosen as a method to confirm the conformational changes of the 
fluorescently labeled ezrin constructs bound to solid supported membranes. A designed 
here ezrin chimera with Cy3 label on N-terminus and eGFP at C-terminus was expected to 
produce a FRET signal when bound to the DOGS-Ni-NTA-containing SSLB via its His-tag 
representing the inactive form of ezrin. Binding to the PIP2-containing SSLB was considered 
as activating, therefore decreasing FRET, conditions. The samples were monitored using the 
laser scanning microscope. Phopsphomimicking ezrin mutant ezrinT567D was employed to 
imitate the second activating factor – C-terminal phosphorylation. Such a model was 
designed to elucidate the question of the synergism between PIP2-binding and C-terminal 
phosphorylation (Fig. 5B). 
 
Forster Resonance Energy Transfer (described by Theodor Förster in 1940s) is a very 
sensitive method for measuring distances between molecules and between parts of a single 
molecule and can distinguish molecular units within the distance of several nanometers. 
Thus, it is used in co-localization and conformational studies. The phenomenon of FRET 
represents the non-radiative transfer of energy from an excited donor fluorophore to a 
nearby acceptor fluorophore. FRET does not depend on photon transfer and the acceptor is 
not required to possess properties of a chromophore, but in biological applications FRET is 
commonly when used with two fluorophore molecules. The phenomenon can be explained 
best in terms of the interaction between two dipoles: the electronically excited donor dipole 
oscillates and can pass its energy to the acceptor dipole if it has similar oscillating frequency. 
Thus, the emission spectrum of the donor should in part overlap with excitation spectrum of 
the acceptor. Energy transfer is possible only within short distances of 1 to 10 nm and 50% 
transfer efficiency corresponds to the so called Forster radius. This Forster radius is specific 
for each FRET pair (Fig. 6). A typical and often used FRET pair is CFP (donor) and YFP 
(acceptor), its Forster radius is 4.9 nm (http://zeiss-
campus.magnet.fsu.edu/articles/spectralimaging/spectralfret.html), i.e. if YFP is placed 
within 4.9 nm from CFP Forster transfer can occur and YFP emission can be recorded 
following excitation of CFP. 
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Fig. 6. Forster Resonance Energy Transfer. A: scheme of intramolecular FRET, (a) No FRET occurs due to the large distance 
between the donor and the acceptor fluorophores ( >10 nm), (b) FRET is possible as the distance between the two 
fluorophores is short enough (<10 nm). B: FRET efficiency as a function of the distance between donor and acceptor 
fluorophores. FRET efficiency equals 50% at the Fortser radius or Forster distance.  
Images source - http://www.olympusmicro.com/primer/techniques/fluorescence/fret/fretintro.html.  
 
 
 
The Forster radius is determined by the overlap interval of the FRET pair spectra, the 
quantum yield of the donor, the refractive index of the solution and the orientation of 
fluorophores relative each other, more specifically the orientation factor of dipole moments 
κ. All the mentioned parameters can be measured and calculated, except for the orientation 
parameter. Typically, it is considered to be 2/3 for freely rotating fluorophores, but is hard 
to estimate when the FRET donor and acceptor are attached to macromolecules. Therefore, 
every fluorophore couple should be tested in each particular case to be assigned as a FRET 
pair. In this work, the GFP-Cy3 pair was used for FRET experiments, GFP being the donor and 
Cy3 the acceptor. The fluorescent spectra of GFP and Cy3 are depicted in Fig. 7.  
INTRODUCTION 
 
22 
 
 
 
 
 
 
 
Fig. 7. The overlap in fluorescency spectra of eGFP and Cy3 demonstrates that the fluorophores’ spectral characteristics 
meet FRET requirements. Data obtained from Fluorescence SpectraWiever, ThermoFisher Scientific. 
 
 
  
The FRET signal usually is comprised of some part of the donor emission signal and a 
signal from the direct excitation of the acceptor, they are called the donor spectral bleed-
through and acceptor spectral bleed-through, respectively. These noise signals must be 
taken into account during estimation of the FRET efficiency because they can lead to false 
positive FRET estimations. There are several methods in use to calculate the FRET efficiency 
(a ratio between photons accepted by the acceptor and photons emitted by the donor) and 
account for the mentioned background signals. The most used techniques include sensitized 
emission, acceptor photobleaching, Fluorescence Life Time Microscopy (FLIM) and spectral 
imaging. Sensitized emission or ratiometric imaging is usually applied to measure FRET 
occurring during fast events in the cell. The cell expressing a FRET construct is being excited 
at the donor excitation wave length and emission of the donor and the acceptor are 
recorded. The ratio of the acceptor/donor fluorescence signal is calculated then to estimate 
the energy transfer efficiency. The controls with only donor and only acceptor samples are 
required to subtract the bleed-through signals. The most precise method that does not need 
controls is acceptor bleaching or donor dequenching. FRET between a pair of fluorophores 
results in the quenching of the donor fluorescence due to the resonance energy transfer to 
the acceptor, therefore the destruction of the acceptor fluorescence by the high laser 
intensity leads to de-quenching of the donor, i.e. the donor recovers its quality of emitting 
fluorescent light. The difference in donor emission, in presence of the functioning acceptor 
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and of the bleached acceptor, is calculated and ascribed as FRET efficiency. The bleaching 
time for some acceptors can take up to several minutes and this should be taken in 
consideration when planning experiments. The FLIM technique is another way of 
determining FRET in a precise manner and independent of noise signals. All fluorophores 
can be characterized by decay time in their fluorescence emission, also called fluorescence 
lifetime. During FRET the fluorescence lifetime of the donor is decreased due to the 
presence of the acceptor. Thus, measuring of the donor fluorescence lifetime in the 
presence and the absence of the acceptor can estimate the efficiency of the resonance 
energy transfer. Moreover, this method depends only on the donor features, therefore no 
controls are required. FLIM also can be applied when the acceptor does not possess 
chromophore qualities. The two previous methods require fluorescent microscopes; the 
FLIM is conducted using specifically designed equipment comprising pulsed lasers and single 
photon counting detectors. Spectral imagine of FRET can be performed on 
spectrophotometers in solution or in cells using the specially designed confocal microscopes 
with acousto-optic tunable filters. Emission of the donor and the acceptor is recorded in one 
spectrum following the donor excitation. The spectra of the control samples (only donor, 
only acceptor) should be taken at the identical conditions. The FRET efficiency is then 
determined as EFRET = 1 - (IDA/ID), where IDA is the intensity of the donor emission in the 
presence of the acceptor and ID – in the absence of the acceptor. The spectra of the 
acceptor only are needed to calculate the normalized emission intensity of the FRET sample, 
i.e. to correct for the bleed-through signal.  
  
New application of FRET-acceptor bleaching technique on solid supported bilayers were 
applied to directly demonstrate the conformational activation of ezrin induced by PIP2 
binding and C-terminal phosphorylation and to elucidate the question of correlation 
between these two activation factors. The knowledge of this activation can help us to 
understand the dynamic regulation of the connection between membranes and the 
underlying cytoskeleton. 
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2 Materials 
 
2.1 Chemicals and reagents 
 
Acetic acid (mol. biol. grade)                                  
Acrylamide mix                                                         
Agar-Agar                                                                   
Agarose LE                                                                 
Ammoniumhydroxyd                                               
Beta-Mercaptoethanol                                              
Boric acid, buffer grade                                                      
Bovine serum albumin                                            
Bromophenol blue                                                   
Coomassie Billiant Blue                                           
Cy3 mono-reactive NHS ester                                
Dinatriumhydrogenphosphate                               
Dimethyl sulfoxide (DMSO) (mol. biol. grade)    
Dimethyl sulfoxide (DMSO) anhydrous                
Dithiothreitol (DTT)                                                 
DMEM 4500 mg glucose/l w/o L-glutamine       
DOGS-Ni-NTA (1,2-dioleoyl-sn-glycero-3-[(N-
(5-amino-1-carboxypentyl)iminodiacetic 
acid)succinyl] Ni salt) 
DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine)                                        
DyLight405 maleimide                                            
EDTA (mol. biol. grade)                                           
Epidermal growth factor human >=97% SDS-
PAGE (EGF)    
Ethanol (mol. biol. grade)                                       
Ethidium bromide                                                    
FCS                                                                              
G418 sulphate                                                          
Glycerol (mol. biol. grade)                                      
Hepes (cell culture grade)                                      
Hydrochloric acid 37 % (analysis grade)              
Hydrogen peroxide                                                        
IPTG                                                                            
Isopropanol (mol. biol. grade)                               
Imidazole                                                                                
Kalium chloride (mol. biol. grade)                         
Kanamycin sulphate                                                 
L-Glutamine 200 mM                                               
AppliChem 
Roth 
AppliChem 
Biozym 
Sigma 
Roth 
AppliChem 
Serva 
Sigma 
AppliChem 
GE Healthcare 
Roth           
AppliChem 
Life Technologies  
AppliChem 
Sigma 
 
 
Avanti Polar Lipids, Inc. 
 
Avanti Polar Lipids, Inc. 
ThermoFischer Scientific 
AppliChem 
 
Sigma 
AppliChem 
Sigma 
Biochrom 
PAA 
AppliChem 
AppliChem 
AppliChem 
Grüssing GmbH Analytika 
AppliChem 
AppliChem 
Roth 
Roth 
AppliChem 
Lonza 
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Lipofectamine 2000                                                 
Loading Buffer 6x                                                     
Low fat milk powder                                               
Methanol (technical grade)                                    
Mowiol 4-88                                                              
Natriumdihydrogenphosphate                              
Opti-MEM                                                                  
PBS w/o Ca2+, Mg2+                                                   
Penicillin/Streptomycin                                           
Paraformaldehyde (PFA)                                         
Phalloidin-TRITC                                                        
PI(4,5)P2 (L-α-phosphatidylinositol-4,5-
bisphosphate, purified from porcine brain 
with a fatty acid composition primarily 
composed of 18:0, 18:1, and 20:4 acyl 
chains)   
PIPES (buffer quality)                                                
Phenylmethanesulfonylfluoride PMSF  
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine)  
Protease inhibitor cocktail tablets                         
SDS pellets (biochem. grade)  
Silicon wafers                                 
Sodium azide                                                              
Sodium chloride (mol. biol. grade)                         
Sodium Citrate                                                           
Tetramethylethylenediamine (TEMED)                 
Trichlormethan/Chloroform                                    
Tris                                                                                
Triton X-100                                                                
Trypsin-EDTA                                                              
Tween 20                                                                    
Yeast extract BioChemica                                  
Invitrogen 
Thermo Scientific 
AppliChem 
AppliChem 
Calbiochem 
Roth 
Invitrogen 
PAN Biotech 
Lonza 
Sigma 
Sigma 
 
 
 
 
Avanti Polar Lipids, Inc. 
AppliChem 
(Biochemica) AppliChem 
 
Avanti Polar Lipids, Inc.  
Roche      
Roth      
Silicon materials 
AppliChem   
AppliChem  
Roth                                                            
AppliChem 
Roth 
AppliChem 
AppliChem 
PAA 
AppliChem 
AppliChem 
 
 
2.2 Markers 
 
1kb GeneRuler Plus DNA ladder 
Page Ruler Plus Prestained Protein Ladder 
Protein Marker lll, prestained 
Thermo Scientific 
Thermo Scientific 
Peqlab 
                    
 
2.3 Kits 
 
Copmassie Plus – The Better Bradford Assay 
Kit     
 
Thermo Scientific 
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HiYield PCR Clean-up/Gel Extraction Kit            
HiYield Plasmid Mini DNA-Kit                             
KAPAHifi PCR Kit with dNTP Mix                         
PureLink HiPure Plasmid Filter Maxiprep Kit     
Sued-Laborbedarf GmbH 
Sued-Laborbedarf GmbH 
Peqlab 
Invitrogen 
 
 
2.4 Antibodies 
 
2.4.1 Primary antibodies 
 
 mAB/pAB Species Dilution Manufacturer 
anti-ezrin pAB Rabbit WB 1:10000 Millipore 
anti-ezrin mAB Mouse IF 1:250 BD 
anti-GFP pAB Rabbit WB 1:10000 Invitrogen 
anti-T7-tag mAB Mouse WB 1:10000 Novagen 
 
 
2.4.2 Secondary antibodies 
 
 Target 
species 
Dilution  Manufacturer  
IRDye 680CW Conjugated Goat Anti-Mouse IgG mouse 1:14000 Li-cor 
IRDye 800CW Conjugated Goat Anti-Rabbit IgG rabbit 1:14000 Li-cor 
Alexa Fluor 647 Donkey Anti-Mouse IgG mouse 1:250 Dianova 
 
 
2.5  Enzymes 
 
α-Chemotrypsin from bovine pancreas 
Grade 1  
KAPAHifi DNA polymerase                                    
T4 DNA ligase                                                            
FastAP thermosensitive alkaline 
phosphotase     
Restriction enzymes: EcoR1, Sal1, Xba1, 
Dpn1              
 
Applichem 
Peqlab 
Fermantas 
 
Thermo Scientific 
 
Fermentas 
 
 
2.6 Cell lines  
 
A431 cell line – adherent epithelial cells, derived from human epidermoid carcinoma. High                                                                                                                                                     
                          espression  level of EGFR. 
 
HeLa cell line – adherent epithelial cells, derived from human cervical adenocarcinoma.  
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HEK293T cell line – adherent epithelial cell line, derived from human embryonic kidney cells, 
is a modification of HEK293 cell line. HEK293T express SV40 T-antigen gene what enhances 
the production of transfected plasmids.  
 
 
2.7 Bacterial strains  
 
E. coli BL21(DE3)pLysS 
Genotype: F‐ ompT hsd SB (rB‐mB‐) gal dcm (DE3) pLysS (Camr)   GE healthcare biosciences 
 
E. coli DH5α  
Genotype: F+, deoR, endA1, gyrA96, hsdR17, (rk‐,mk+), glnV44, thi‐1, recA1,relA1, supE44, 
Φ80ΔlacZΔM15, thi‐1, Δ(lacZYA‐argF)U169   Promega 
 
Rosetta 
Genotype: F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR) Addgene 
 
JM110 
Genotype: rpsL thr leu thi-1 lacY galK galT ara tonA tsx dam dcm supE44 ∆(lac-proAB) 
from prof. Prüfer AG, Istitute of Biology and Biotechnology of Plants, Muenster 
 
 
2.8 DNA-constructs  
 
2.8.1 Eukaryotic and bacterial expression vectors 
 
pET28a(+)  is a vector for protein expression in E. coli, under T7 promoter with N-terminal 
(His)6‐tag and additional C-terminal (His)6-tag, carries kanamycin resistance gene, Clontech. 
 
pET24b(+) is a vector for protein expression in E.coli, under T7 promoter with N-terminal 
(His)6‐tag, also additional C-terminal (His)6-tag, carries kanamycin resistance gene, 
Clontech. 
pEYFP-C1 is a vector for expression of proteins with N-terminal enhanced-YFP tag in 
eukaryotic cells, under CMV promoter, carries G418-resistance gene, Clontech. 
 
pECFP-N1 is a vector for expression of proteins with C-terminal enhanced-CFP tag in 
eukaryotic cells, under CMV promoter, carries G418-resistance gene, Clontech.  
 
pEGFP-N1 is a vector for expression of proteins with C-terminal enhanced-GFP tag in 
eukaryotic cells, under CMV promoter, carries G418-resistance gene, Clontech. 
 
 
 
Construct  Vector  Insert  Reference 
Ezrin-CFP pECFP-N1 Ezrin This thesis 
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His-YFP-Ezrin-CFP pEYFP-C1 Ezrin-CFP, addition of 
(His)6-tag 
This thesis 
Ezrin-eGFP pEGFP-N1 Ezrin Annika Heil 
Ezrin-eGFP pET28a(+)ezrin eGFP This thesis 
EzrinT567D-eGFP pET28a(+)ezrinT567D eGFP This thesis 
His-ezrin pET28a(+) Ezrin M. Koltzscher 
His-ezrinT567D pET28a(+) Mutation of the 
Threonine567 in 
Ezrin-wt 
J. Austermann 
eGFP pET24b(+)eGFP 
 
eGFP A.Schmidt 
 
 
2.8.2 Oligonucleotides 
 
Restriction free cloning of pET24b(+)EzrGFP (van den Ent and Löwe 2006). 
Forw: 5´- TCCGAGGCCCTGTTAAAGCTTGCGGATGGGTCGGGATCCAGTAAAGAAGA-3´ and 
Rev: 5´- AGTGCGGCCGCAAGCTTCTCGACTTAGCCATGTGTAACCCCAGCAGCTG -3´ 
 
To introduce an 6xHis-tag for purification from eukaryotic cells following primers were used:   
Forw:  5´ - GAGCCGCCATGCATCATCATCATCATCATGGAGGA and  
Rev:  5` - TCCTCCATGATGATGATGATGATGATGCATGGCGGCTC. 
 
 
2.9 Equipment 
 
Amicon Ultra-4 Centrifugal Filter Unit 50k  
Cell scraper  
Coverslips 22 X 22 mm, Nr. 1  
Cryo tubes, 2 ml  
Dialysis Slide-A-Lyser, 3 - 12 ml, 10 kD cutoff  
Illustra NAP 10 size exclusion columns   
Quartz cuvettes  
Microscope slides  
Microwell 96-well plates, flatbottom  
Nitrocellulose membrane Protan BA85, 0.45 
µm  
Parafilm  
Tissue culture dishes (diff. sizes)  
Whatman paper  
Millipore 
Greiner 
Diagonal 
Greiner 
Pierce 
GE Healthcare 
Hellma 
Diagonal 
Greiner 
 
Diagonal 
American Nat. Can 
Greiner 
Diagonal 
 
 
2.10 Devices 
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Bacteriological incubator  
Balances  
Centrifuge Avanti J-25  
Centrifuge Optima TL Ultracentrifuge  
Centrifuge Optima L-70K Ultracentrifuge  
Centrifuge Megafuge 1.0R  
Counting chamber  
DMIL inverted microscope 
EVOS digital inverted microscope  
Fluorimeter FluoroMax-2 
French Pressure Cell Press  
Incubator Heracell 240 I CO2  
Incubator-shaker refrigerated Innova 4230  
LSM 780/Axio Observer  
LSM 710      
Microwave oven    
Minigel system  
Minigel system  
Mini Trans-Blot  
NanoDrop ND-1000 UV/Vis-
Spectrophotometer  
Odyssey Infrared Imaging System LI-COR  
pH meter 766  
Pipetboy Acu Integra 
Plasma cleaner electronic diener   
Power Pack P25 power supply  
RIfS   
 
RoboCycler gradient 96  
Sonifier 250  
SpeedVac SC110                    
Spectrophotometer DU640  
Spectrophotometer UV-visible 50scan  
Sterile work bench Herasafe HS12  
Sterile work bench  
Table centrifuge Biofuge pico  
Thermomixer 5436  
Vortex  
UV lamp Solo TS Imagine System  
Water bath 1008  
Memmert 
Quintix Sartorius 
Beckman 
Beckman 
Beckman 
Heraeus 
Roth 
Leica 
Peqlab 
Instruments S.A. 
SLM-Aminco 
Thermo Scientific 
New Brunswick Scientific 
Carl Zeiss Microscopy GmbH 
Carl Zeiss Microscopy GmbH 
Panasonic 
Peqlab 
Biometra 
Cell Bio-Rad 
 
Peqlab 
Biosciences 
Calimatic Knick 
Biosciences 
Plasma-Surface-Technology 
Biometra 
Self-assembled in Claudia Steinem lab, 
Göttingen 
Stratogene 
Branson G.Heinemann 
Omnilab 
Beckman 
Varian 
Heraeus 
BDK Luft und Reinraumtechnik GmbH 
Heraeus 
Eppendorf 
Genie Scientific Industries 
Biometra 
GFL 
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3 Methods 
                      
 
3.1 Cell biology methods 
 
3.1.1 Cultivation of adherent eukaryotic cells 
 
HeLa, A431 and HEK293T were cultivated in high glucose DMEM (4.5 g/L) supplemented 
with 10%  FCS, 2mM L-glutamine, 100 U/ml Penicillin and 10mg/ml Streptomycin at 37°C 
and 7% CO2.  
For passaging, the medium was aspirated and TE solution was added for 5 min for HeLa 
cells and 15-20 min for A431 cells, at 37°C. For HEK293T cells trypsinization was not needed, 
the cells could be detached with gentle medium flow through a pipette.  Thereafter the cells 
were centrifuged at 800 rpm for 4 min at 20°C. Pelleted cells were re-suspended in the fresh 
medium and seeded at a required density.  
 
3.1.2 Cryo-stocks 
 
Cells were grown in 10-cm Petri dishes up to 90% confluency, trypsinized and pelleted. 
The pellet was suspended in 1 ml of fresh medium containing 10% DMSO. Then the cells 
were frozen in freezers at -80°C and placed for storage in liquid nitrogen. 
 
3.1.3 EGF stimulation experiments 
 
A431 cells were starved for 5-7 hours in DMEM medium without FCS in 24-well dishes at 
a confluency of 50-70%. After stimulation with 33 nM EGF for 10 min at 37°C cells were fixed 
with PFA (see 3.1.4.1). For each experiment 3 samples were generated: 1-non starved cells, 
2-starved, not stimulated cells, 3-starved and then stimulated cells.  
 
3.1.4 Confocal immunofluorescence imaging 
 
3.1.4.1 PFA fixation of cells 
 
Cells were seeded in 24-well plates, on cover slips for confocal microscopy. Medium was 
aspirated and 4% PFA in PBS solution was immediately added to the cells for 5 min. 
Subsequently, the cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min and 
incubated with glycin buffer for 10 min 3 times. Then blocking buffer was then added for 30 
min. After every new step the cells were washed with PBS twice. All steps were carried out 
at RT. 
 
4% PFA in PBS: 
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Four grams of PFA was heated in 100 ml of PBS+/+, with 1mM NaOH, at 70°C for 2-3 hrs 
with constant stirring. After the solution turned transparent it was cooled down to room 
temperature and the pH was adjusted to 7.4 with HCl. Storage at -20°C. 
 
Glycin buffer: 
130 mM NaCl 
7 mM Na2HPO4  
3.5 mM NaH2PO4  
100 mM glycin  
Store at 4°C. 
 
Blocking buffer: 
130 mM NaCl 
7 mM Na2HPO4  
3.5 mM of NaH2PO4 
7.7 mM NaN3 
0.02% BSA 
0.2% TritonX100 
0.05% Tween20 
0.1% FCS  
Store at 4°C. 
 
 
3.1.4.2 Staining with antibodies 
 
Cells were incubated with primary antibodies in blocking buffer for 1 hour at RT or 
overnight at 4°C, washed twice with PBS for 15 min and subsequently stained with 
secondary antibodies for 1 hour at RT, then washed for 20 min with PBS. For actin staining 
TRITS-Phalloidin was added simultaneously with the secondary antibodies.  
At the end the cells were washed 2 times with water. Thereafter the cover-slips with the 
cells were mounted on a drop of Moviol 4-88 (1% N-propyl-gallat and 2 mM sodium azide 
added) on a glass slide.  After drying overnight at 4°C the cells were inspected by 
microscopy.  
 
3.1.4.3 Laser scanning microscopy 
 
Preadjusted settings for eYFP, eCFP, eGFP, Alexa647 and Phalloidin were used on a LSM 
780 (confocal laser scanning microscope, Zeiss) with x63 oil immersion objective. The LSM 
Image Browser was used to process the images.  
 
 
3.1.5 Transient transfection 
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Transfections were performed with Lipofectamine 2000 according to the manufacturer’s 
protocol. An important modification, antibiotics were not added to the cultivation medium 
before 24 hours after transfection to enhance cell survival.  
 
 
3.1.6 Stable transfection 
 
Cells were transfected as described above. Efficiency of transfection was analyzed using a 
fluorescence microscope EVOS (AMG), detecting fluorescence of the ectopically expressed 
YFP (or GFP)-fused protein in the cell. Sub-clones were selected in medium containing 1.4 
µg/ml G418 antibiotic using series of dilutions in 96-well plates. Briefly, cells were diluted to 
a concentration 0.7 cells per well and grown for 2 weeks, changing medium every 4 days. 
Selected clones were grown in 20 cm dishes with the defined amount of G418 antibiotic in 
the medium.  
 
 
3.2 Molecular biology methods 
 
3.2.1 Plasmids cloning 
 
Two cloning strategies were used.  
 
3.2.1.1 Restriction free cloning (van den Ent and Löwe 2006) 
 
Thirty-nucleotides primers were used to amplify a given region from a donor plasmid. 
This region, which is to be inserted into the acceptor vector, is used as “primer” for a second 
PCR reaction to amplify the whole acceptor vector with inserted region. Dpn1 digestion is 
then used to destroy the parent plasmid. To confirm the succesfull cloning the constructs 
were sequenced (using BigDye polymerase mix in the facility of Universitäts Klinikum 
Münster).  Then the constructs obtained were transformated into DH5α strain of E.coli for 
further amplification and purification.  
The final pET28a(+)EzrGFP construct was generated using the GFP sequence from an 
pET24b(+)GFP vector (donor vector) and pET28a(+)ezrin plasmid (acceptor vector), (Fig. 8). 
The following primers were used:  
Forw: 5´- TCCGAGGCCCTGTTAAAGCTTGCGGATGGGTCGGGATCCAGTAAAGAAGA-3´ and 
Rev: 5´- AGTGCGGCCGCAAGCTTCTCGACTTAGCCATGTGTAACCCCAGCAGCTG -3´ 
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Fig. 8. Schematic representation of the restriction free cloning of ezrin-GFP and T567D-GFP constructs. 
 
 
 
A plasmid for expressing the phosphomimicking mutant, DGFP, was generated with the 
same set of primers using the pET28a(+)EzrT567D as an acceptor plasmid (where Threonin 
567 was changed to Aspartic acid) for inserting the eGFP sequence. 
PCR conditions for clonning: 
   
 
1st PCR  
 
Denaturation 98°C 4min 
 
30 cycles 
Denaturation 98°C 30s 
Annealing  61°C 45s 
Extension 72°C 1min 
Final 
Extension 
72°C 6min 
 
2nd PCR  
Denaturation 98°C 4min 
 
35 cycles 
Denaturation  98°C 30s 
Annealing  54°C 30s 
Extension  72°C 4min 
Final 
Extension 
72°C 4min 
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HiYield PCR Clean-up/Gel Extraction Kit (SLG) was used to purify DNA after each step of 
amplification. 
 
3.2.1.2 Cut-ligation method 
 
Certain restriction enzymes were selected to remove an insert from a donor plasmid and 
T4 DNA ligase was used to fuse the insert with the accepting vector.  All the manipulations 
were performed according to manufacturer’s recommendations (see Materials). 
 
EcoR1 and Sal1 restriction enzymes were used to remove the ezrin coding region from 
the pET28a(+)ezrin plasmid, ligated into the pECFP vector. EcoR1 and Xbal1 were then used 
to cut out the ezrinCFP part, which was then inserted in the pEYFP vector (Fig. 9).  To 
introduce a 6xHis-tag for purification from eukaryotic cells following primers were used:   
Forw:  5´ - GAGCCGCCATGCATCATCATCATCATCATGGAGGA and  
Rev:  5` - TCCTCCATGATGATGATGATGATGATGCATGGCGGCTC. 
 
1 step of cut-ligation cloning: inserting ezrin sequence in pECFP-N1 vector 
 
 
 
 
2 step of cut-ligation cloning: inserting ezrin-CFP in pEYFP-C1 vector 
 
   
 
 
Fig. 9. Molecular cloning: two-steps scheme of cut-ligating method. 
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All the cloned constructs were verified by sequencing (using BigDye polymerase mix in 
the facility of Universitäts Klinikum Münster) and transformated into DH5α strain of E.coli 
for further amplification and purification. 
 
The purification of the plasmid fragments after restriction digestion was performed using 
HiYield PCR Clean-up/Gel Extraction Kit (SLG) after separation of the fragments during DNA 
gel-electrophoresis (see. 3.3.3 of Methods). 
 
 
3.2.2 Maxi-preps 
 
3.2.2.1 E.coli transformation 
 
Frozen (80°C) 50 µl aliqoutes of chemically competent DH5α (for plasmid prep) or BL21 
(for protein expression) strains were thawed on ice. 50-300 ng of desired plasmid DNA was 
added and the bacteria left on ice for 30 min, followed by a heat-shock at 42°C for 1 min and 
10 more min incubation on ice. The bacteria were then mixed with 1ml of LB medium 
without antibiotic and cultivated for 40 min at 37°C at 180 rpm. Bacteria were plated on 
agar plates with kanamycin (30 µg/ml). 
 
3.2.2.2 Plasmid prep 
 
E.coli DH5α were used for plasmid amplification. A chosen colony from a kanamycin agar 
plate was pre-cultured overnight at 37°C, 180 rpm in LB medium with 30 µg/ml of 
kanamycin. Bacteria were then harvested, lysed and the plasmid DNA purified using the 
maxi-prep kit according to the manufacturer (see Materials). 
 
 
3.3 Biochemical methods 
 
3.3.1 SDS-PAGE 
 
Protein samples were boiled at 95°C for 5 min in SDS-SB and then separated in acrylamyd 
gels using a combination of 2 gel layers: stacking gel (5% acrylamid) and separating gel (10% 
acrylamid). 200mV current was applied to the electrophoresis chamber for 40-60 min. 
Gels were stained in Coomassie solution for 30 min at RT and washed in destaining buffer 
for 2-3 hours. 
 
Sample buffer (1x SDS-SB):  
62.5 mM Tris ph 6.8  
2% SDS  
10% glycerine  
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300mM 2-mercaptoethanol  
~ 0.1% (w/v) bromphenol blue  
 
Stacking gel (5%):  
17% acrylamid / bisacrylamid  
125 mM Tris pH 8.8  
0.1 % SDS  
0.1 % APS  
0.1 %  TEMED 
 
Separating gel (10%/12%):  
10% or 12% acrylamide/bisacrylamid*  
375 mM Tris pH 8.8  
0.1 % SDS  
0.1 % APS  
0.04 % TEMED  
*30 % acrylamide and bisacrylamide 
stock solution at a ratio of 37.5:1 
 
 
Running buffer:  
25 mM Tris  
2% SDS  
192 mM glycine  
 
 
 
Coomassie staining buffer: 
40% methanol 
10% acetic acid (100% stock) 
0,1% Coomassie Brilliant Blue R250 
50% ddH2O 
 
Destain buffer: 
45% methanol  
10% acetic acid 
45% ddH2O 
 
 
3.3.2 Western Blot analysis 
 
3.3.2.1 Proteins transfer 
 
Acrylamid gels were overlaid with nitro-cellulose membranes were placed between filter 
paper and fiber pads, put in gel holder cassettes and then inserted in a mini trans-blot tank 
system. An ice block was also placed in the tank to cool the system. Transfer was performed 
at 300 mA per tank for 1h in 4°C cold transfer buffer at RT.  
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Transfer-buffer:  
0.5 M Tris  
0.5 M Boric acid  
In ddH2O  
 
3.3.2.2 Immunodetection of proteins. 
 
Blot membranes were blocked with 5% milk powder in TBS-T buffer for 30 min at RT. 
Primary antibodies were added for 30 min at RT or overnight at 4°C in the same solution. 
Secondary antibodies were added to the membranes in the milk solution after 10 min, 3 
times washing with TBS-T buffer. Secondary antibodies linked to IR-dyes for IR-detection (LI-
CORE system) were incubated with the membranes for 45 min at 1:10000 dilution. Blot 
membranes were washed again 3 times for 10 min in TBS-T and then processed in the LI-
CORE detection system. 
 
TBS-T: 20 mM Tris  
150 mM NaCl  
0.2 % (w/v) Tween 20  
pH 7.5 with HCl  
in ddH2O  
 
3.3.2.3 Stripping of blot membranes 
 
Primary and secondary antibodies can be stripped from Western blot membranes in 
stripping buffer for 30-50 min at 52°C. Following stripping membranes were then thoroughly 
washed with TBS-T and primary and secondary antibodies could then be applied to the 
membranes again as described above.  
 
Stripping buffer: 
625 µl Tris 
2 ml SDS 10% 
69 µl mercaptho-etanol 
up to 10 ml with H2O 
 
 
3.3.3 DNA gel-electrophoresis 
 
DNA gel-electrophoresis was used to separate plasmid fragments after enzymatic 
restriction. To prepare gels, the agarose LE (0.5%) was suspended with TAE buffer and 
dissolved upon heating in the microwave. Then it was cooled to 40-45 ̊C, and ethidium 
bromide was added at ratio 1:10000 (v:v). The agarose solution was then poured into the 
gel chamber and left at RT to polymerase. The samples were mixed with the 6x Loading 
Buffer (ThermoScientific) and loaded in the gel pockets. Running time constituted 40-60 min 
at 100 mV. 
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Purification of the desired plasmid fragments were performed using the HiYield PCR 
Clean-up/Gel Extraction Kit (SLG) as described by manufacturer. 
 
TAE buffer, pH 8.0:  
40 mM Tris-HCl 
0.1 % acetic acid 
1 mM EDTA 
 
 
3.3.4 Bacterial expression and purification of the proteins 
 
The BL21 E.coli strain was used for expression of recombinant proteins. Bacteria were 
transformed with pET28a(+)Ezrin/D-GFP plasmids and plasmid selection was performed by 
addition of 30 µg/ml kanamycin to the medium.  Pre-cultured bacteria were grown in LB 
medium at 37°C, in a bacterial shaker at 180rpm until ab OD of 0.6. Protein expression was 
induced with 1mM IPTG and the culture was cultivated at the same conditions for 3-5 hrs. 
Bacterial cells were harvested by 10 min centrifugation at 4krpm, 4°C and the pellet was 
resuspended in lysis buffer and homogenized in a French press. The cells debris was 
separated by 1h of ultra-centrifugation at 30krpm, 4°C and the supernatant incubated on a 
shaker for 30 min at 4°C with Ni-NTA agarose beads equilibrated in lysis buffer. The beads 
were transferred to a column, washed with wash-1 and wash-2 buffers and protein bound 
via the 6xHis-tg were eluted with elution buffer.  
For the expression of untagged ezrin and ezrinT567D mutant the freeze-thaw method 
with subsequent ultrasonication (cycle duty=60%, output control=5) was used to disrupt 
bacterial cell walls and lysate cells.  
The quality of the purified proteins was analyzed using SDS-PAGE and Western blot. For 
further experiments proteins were dialyzed against the buffer required.  
 
LB-medium:  
1 % Trypton  
0.5 % yeast extract  
1 % NaCl  
30 μg /ml kanamycin 
Lysate buffer: 
1mM EDTA pH=8.0 
10mM b-mercaptoethanol                                                                                                                                                                                                      
20mM imidasol                                                                                                                              
300mM NaCl                                                                                                                                                    
40mM HEPES pH7.4                                                                                                                                  
1mM PMSF 
Wash-1 buffer: 
40 mM HEPES, pH 7.4  
25 mM imidasol, pH 7.4  
150 mM NaCl  
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10 mM beta-mercaptoethanol   
1mM PMSF  
Wash-2 buffer:  
40 mM HEPES, pH 7.4  
35 mM imidasol, pH 7.4  
150 mM NaCl  
10 mM beta-mercaptoethanol  
1 mM PMSF  
Elution buffer: 
500 mM imidasol, pH 7.4 
150 mM NaCl  
10 mM beta-mercaptoethanol   
1 mM PMSF  
 
 
3.3.5 Recombinant expression and purification of proteins from HEK293-T cells 
 
HEK293T cells expressing His-tagged YFPezrinGFP were scratched from Petri dishes 
containing DMEM and pelleted at RT, 800 rpm for 4 min. All further manipulations were 
performed on ice. The cell pellet was resuspended in cold low salt buffer and cells were then 
lysed by pushing the suspension through a syringe needle Nr1 from BD MicrolanceTM 3. The 
lysis level was detected analyzing a drop of the suspension under the optical microscope. 
Cellular debris was removed by ultracentrifugation (40 min, 20000 rpm, 4°C). Supernatants 
containing proteins were then dialyzed against HEPES+ buffer and incubated with pre-
equilibrated Ni-NTA agarose beads for 30 min at 4°C. Column purification was then 
performed as described above (see 3.3.4.). 
10 ml of low salt buffer was required for cell pellets collected from 150 20cm-Petri dishes 
with cells grown to a confluency of 90-100%. 
Low salt buffer pH7.4: 
10 mM HEPES  
0.5 mM EDTA  
1 mM DTT  
Protein inhibitor tablet 
HEPES+ buffer pH7.4: 
40 mM HEPES 
150 mM NaCl 
2 mM DTT 
1 mM PMSF 
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3.3.6 Fluorescent labeling of proteins 
 
3.3.6.1 Fluorescent labeling with Cy3TM Mono NHS ester 
 
Cy3 NHS ester dye (1 mg of purchased powder dissolved in 200 µl of anhydrous DMSO) 
was used for labeling the N-terminal amino-group of C-terminal GFP-fused proteins. To 
achieve a preferred binding of the dye to the N-terminal α-amino group, the manufacturer’s 
protocol was modified by conduction the labeling pH6.5 in 1:1 molar ratio at RT for 3-4 
minutes. Removing of the excess dye was performed immediately on a Sephadex size 
exclusion column. Labeling efficiency was quantified by running the protein samples on SDS 
gel and visualizing labelled proteins using an UV-lamp UVsolo TS. For subsequent 
experiments the labeled proteins were dialyzed against the buffer required.  
 
Labeling buffer – PIPES buffer pH6.5: 
10 mM PIPES 
150 mM NaCl 
 
3.3.6.2 Fluorescent labeling with DyLight405-maleimide 
 
One milligram of DyLight405-maleimide was dissolved in 100 µl of anhydrous DMF. Prior 
to the reaction proteins were reduced with a 100-molar excess of DTT for 30 min at RT and 
then dialyzed against labeling buffer. Alternatively, the TCEP reducing agent was used in the 
same molar ratio for 10 min at RT without subsequent dialysis. Dye and protein were mixed 
in a molar ratio 1:1 and incubated at 4°C overnight with slow shaking. Excess dye was 
removed on a Sephadex size excluding column. 
 
Labeling buffer – HEPES, pH7.4: 
10 mM HEPES 
150 mM NaCl 
 
3.3.6.3 UV-vis specta 
 
Light absorbance of Cy3 labeled constructs was measured using a 50scan UV-visible 
spectrophotometer (Varian) at 280 nm (optimal absorbance of aromatic amino acids in 
proteins) and 550 nm (Cy3 absorbance maximum). Cy3 labeling efficiency was calculated 
using the formula: 
 
 
 
where D/P corresponds to the dye-protein ratio, i.e. the labeling efficiency, A280 and A552 are 
the maximum absorptions of the aromatic amino acids and the cross-linked Cy3 dye, 
respectively. Factor of 0.08 – the correction for the dye absorption at 280 nm. Extinction 
coefficients:    ex.cCy3=150000 M-1cm-1,   Eezrin/ezrinT567D=64390 M-1cm-1,   EEzrGFP/DGFP=87710   
M-1cm-1.  
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The extinction coefficient of ezrin was taken from the database (http://www.signaling-
gateway.org/molecule/query?afcsid=A000892), the extinction coefficient for EzrGFP was 
calculated as described (Pace et al. 1995). The extinction coefficients of the mutants were 
taken as those of wild type, since exchange of threonine to aspartic acid does not influence 
spectral properties of proteins. 
 
3.3.6.4 Fluorometric measurements 
 
Fluorescence excitation and emission spectra were recorded with a fluorimeter 
FluoroMax-2 (Instruments S.A.) in quartz cuvettes (Hellma), light path 10 mm. Excitation 
scan and emission scan were read using the settings provided in the FlouroMax software.  
 
 
3.3.7 Bradford assay 
 
Protein concentrations were determined using the Coomassie Plus Bradford Protein 
Assay Reagent. An aliquot of a protein in water was mixed with Bradford Reagent at a ratio 
of 1:1, total volume 1 ml, and incubated 10 min at RT. Absorption was then measured at 595 
nm using a spectrophotometer. Concentrations were calculated based on standard curve 
obtained using 0.1, 0.5, 1, 2, 4, 6, 8, 10 µg of BSA. 
 
 
3.3.8 Liposomes preparation  
 
Lipid mixtures were prepared from methanol:chloroform (1:1) lipid stocks. Briefly, 
solutions were dried in nitrogen flow and subsequently in a SpeedVac at 37°C for 4-5h. Dried 
lipids films were dissolved in the required buffer solution and incubated at 50°C (water 
bath) for 45 min, being thoroughly vortexed for 1 min every 15 min. In that way multi-
lamellar liposomes were formed, which were used in liposomes pelleting assay.  
For the FRET experiments employing solid supported membranes and for RIfS experiments 
lipid films were dissolved in the required buffer and incubated at RT for 30 min, vortexing 
after 20, then 5 and 5 min after the buffer had been added. Next, the suspension was 
treated in a sonicator at 60% of duty cycle, output control 4, for 15 min 2 times, changing 
heated water in the sonicator reservoir to cold water in between.  This procedure resulted 
in the formation of SUVs (small uni-lamellar vesicles). 
 
 
3.3.9 Liposomes pelleting assay 
 
Three different types of multi-lamellar vesicles were prepared (3.3.8. of this manuscript): 
1) 92:8 molar ratio POPC:PIP2, 2) 92:8 molar ratio DPPC:DOGS-Ni-NTA. Total lipid 
concentration – 0.8 mg for 1ml of E1 buffer. 50 mg of protein of interest in E1 buffer was 
added to 100 µl of the vesicles suspension, filled with the buffer up to 200 µl and incubated 
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at RT for 1h. After ultra-centrifugation at 60 krpm at 4°C, pellet and supernatant fractions 
were collected and analyzed by SDS-PAGE. 
 
E1 buffer pH7,4: 
20 mM Tris 
50 mM KCl 
0.1 mM EDTA 
0.1 mM NaN3 
 
 
3.3.10 Supported lipid bilayer preparation and protein binding 
 
SUVs suspensions, prepared as described in 3.3.8. of this manuscript (total lipid 
concentration – 0.6 mg/ml), were applied to hydrophilized silicon substrates (or wafers, 
wafer size – 0.8cmx1cm), fixed in  plastic chambers for 1h at RT, then carefully washed with 
a corresponding buffer. Spreading of SUVs on the surface leads to the formation of a 
continuous lipid bilayer. Defined amounts of protein were dropped on the wafer covered 
with the lipid bilayer, distributed gently via pipeting and left for binding at 4°C overnight. 
Thereafter, wafers were carefully washed with the respective buffer. Samples were then 
examined under the microscope. 
Lipid films contained PIP2/POPC or DOGS-Ni-NTA/DOPC, molar ratio given: 8% PIP2 – 92% 
POPC, 8% DOGS-Ni-NTA – 92% DOPC, 4% PIP2 – 96% POPC, 4% DOGS-Ni-NTA – 96% DOPC, 
2% PIP2 – 98% POPC, 2% DOGS-Ni-NTA – 98% DOPC. 
For the PIP2 containing liposomes low-pH citrate buffer is required to properly immobilize 
SUVs on the surface and spread the correct bilayer (Braunger et al. 2013). E1 buffer was 
then used as washing buffer. DOGS-Ni-NTA containing liposomes were immobilized and 
spread using E1-Ca2+ buffer for the 1st step, and E1-EDTA-free buffer for the second step.  
Protein binding to PIP2 containing lipid bilayers and subsequent washing was optimal in E1 
buffer. For binding of protein to DOGS-Ni-NTA containing lipid bilayers E1-EDTA-free buffer 
was used. 
 
To hydrophilize silicon substrates (100 nm SiO2 layer for LSM experiments, 5000 nm oxide 
layer for RIfS) wafers were heated to 70°C in a solution containing 
H2O2(30%):NH4OH(25%):H2O 1:1:5 for 15 min, while stirring. Before using in experiments 
wafers were thoroughly washed with distilled water and dried under nitrogen. For the RIfS 
experiments the wafers were treated with oxygen plasma for 6 min in the ozonizer 
(electronic diener Plasma-Surface-Technology).  
 
Citrate buffer pH4.8: 
20 mM Na-Citrat 
50 mM KCl 
0.1 mM EDTA 
0.1 mM NaN3 
 
E1-Ca2+ buffer, pH7.4 = E1 buffer with no EDTA and 2 mM CaCl2 added. 
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E1-EDTA-free buffer = E1 with no EDTA 
 
 
3.3.11 Reflectometric Interference Spectroscopy - RIfS 
 
Reflectometric interference spectroscopy was used to observe protein binding to solid 
supported lipid bilayers. The RIfS device detects the interference of white light (500-600nm) 
at the protein layer bound to the solid supported lipid membrane. 
The light source - tungsten halogen lamp - is connected through the illuminating optical 
fiber to the flow chamber which is supplied with a silicon wafer (prepared as described in 
3.3.10.). The collecting optical fiber receives the reflected light. This signal is detected by the 
SpectraSuite software and is analyzed in MATLAB application giving the Optical Thickness-
Time plot as the final result. The RIfS set-up was self-established in the laboratory of Claudia 
Steinem, University of Göttingen (Stephan et al. 2014).  
The vial with liposomes solution was connected with the flow chamber via plastic tubes. 
Liposomes containing either PIP2 or DOGS-Ni-NTA lipids were pumped through the flow 
chamber, where they bound to the hydrophilic wafer and fused into a lipid bilayer. 
Following washing the vial with a protein solution in E1 buffer was connected to the flow 
chamber and left circulating in the system until the equilibrium of the protein-lipid binding 
was reached. 
 
 
3.3.12 Intra- and inter-molecular FRET on supported lipid bilayers 
 
The sample preparation was described above (3.3.10. of Methods).  
The FRET time-bleaching image series were conducted in the CLSM 710 confocal laser 
scanning microscope (Zeiss), using x63 oil immersion objective. To confirm FRET the 
acceptor fluorophore Cy3 was bleached and the fluorescence response of the FRET donor, 
GFP, was monitored. The bleaching and FRAP tool of the Zeiss software were applied. 
Bleaching of Cy3 in the indicated ROI (Regions Of Interest) was carried out at 561nm, 100% 
laser power, with 3 iterations, time series: interval = 0. Excitation wavelength for Cy3 and 
GFP are 561 and 488 nm respectively. The emission was recorded in the interval 493 – 550 
nm for eGFP and 575 – 681 nm for Cy3. The bleaching and FRET efficiency were calculated 
using FRET_calc plugin in JmageJ.  
The experiments were performed in the laboratory of Claudia Steinem, University of 
Göttingen. 
 
3.3.12.1 Statistical analysis. 
 
The collective data was analyzed in R-statistical program applying heteroskedasticity test, 
Shapiro test against normality; Anova type ll test for significance of differences between the 
experimental groups was run on linear fixed effects model (lme) of the data set. 
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3.3.13 Enzymatic protein digest 
 
Chymotrypsin was used to cut Cy3-labeled proteins that were further analyzed by 
Western blot and UV-illumination of the same blot membranes. According to PeptideCutter 
ExPASy (http://web.expasy.org/peptide_cutter/) chymotrypsin can cut 68 times in EzrGFP, 
DGFP and 40 times in ezrin, ezrinT567D (at tryptophan, tyrosine, phenylalanine sites). 
Chymotrypsin powder was freshly dissolved in digestion buffer at a concentration of 1 
mg/ml. To perform the digest this prepared enzyme solution was diluted in the same buffer 
1:100 and 1 µl of the dilution was then mixed with 9 µl of the protein (concentration 3 
mg/ml) in any buffer without EDTA. The reaction time was 5 min at RT. To stop the reaction 
SDS-PAGE sample buffer was added and the mixture was boiled at 95°C for 5 min, then SDS-
PAGE and Western blot were performed. 
 
Chymotrypsin digestion buffer, 10x, pH7.8: 
80 mM Tris/HCl 
100  CaCl2 
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4 Results 
 
 
C-ERMAD and N-ERMAD, in the closed conformation of ezrin, bound to one another in an 
autoinhibitory manner. Several studies have suggested that this association is disrupted 
upon ezrin activation and a resulting change in the conformation (Huang et al. 1999; 
Gautreau, Louvard, and Arpin 2000; Nakamura et al. 1999). Two goals were pursued in this 
project: 1) to demonstrate that the transition of ezrin into the active state involves an 
increase of the distance between C-ERMAD and N-ERMAD and 2) to elucidate the 
contribution of each of the ezrin activation factors in this process.  
Förster Resonance Energy Transfer (FRET) between two fluorophores attached to C- and 
N-terminus of ezrin is a sensitive method for detecting the change in the distance within the 
protein molecule (intra-molecular FRET). Energy transfer from an excited donor fluorophore 
to an acceptor fluorophore in ground state is possible only when they are in the proximity of 
less than 10 nm and results in the fluorescence of the acceptor. For the FRET experiments 
with ezrin I designed the chimera of ezrin and C-terminal eGFP, chemically labeled with the 
Cy3 fluorophore at the N-terminal end of ezrin, as eGFP (donor) and Cy3 (acceptor) have 
been used as efficient FRET (Snapp and Hegde 2006). The attached Cy3 and eGFP are 
expected to give strong FRET signal in the close conformation of ezrin, since C-ERMAD and 
N-ERMAD are bound to each other (Zhu et al. 2007) and the fluorophores are expected to 
be in close proximity. In the activated state the FRET signal should weaken or disappear as 
the distance between the two domains potentially reaches 25 nm (Fehon, McClatchey, and 
Bretscher 2010). Measurements of the FRET efficiency were done using the laser scanning 
microscope LSM 710 (Zeiss) on recombinant proteins bound to solid supported lipid bilayers 
(SSLB). 
To understand the mechanism of ezrin activation the combination of its activation factors 
– PIP2 binding and phosphorylation of T567 threonine on CERMAD were exploited in the 
same experimental set up. I compared behavior of ezrin-wt and the ezrinT567D 
phosphomimicking mutant when the proteins were bound to SSLB either via the PIP2-
binding site or via an N-terminal His-tag. Ezrin binding to DOGS-Ni-NTA lipids via the His-tag 
represents the non-activating condition. The model with solid supported membranes has an 
advantage to experiments within cells, because it allows comparing protein states in 
activating and non-activating conditions without effects of secondary interactions which can 
occur in the cell.  
The mixture of Cy3-labelled ezrin and GFP-fused ezrin were included as an inter-
molecular FRET control. The different protein constructs will be further referred to as 
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following: GFP-fused ezrin – EzrGFP, GFP-fused phosphomimicking mutant of ezrin – DGFP, 
Cy3-labelled EzrGFP – Cy3EzrGFP, Cy3-labelled DGFP – Cy3DGFP, Cy3-labelled ezrin – Cy3Ezr, 
Cy3-labelled phosphomimicking mutant – Cy3D. 
 
 
 
4.1 Expression and purification of the recombinant ezrin, ezrinT567D and their 
GFP-fused derivatives using the BL21 strain of E.coli and HEK293T cells 
 
Ezrin and ezrinT567D were expressed in BL21 E.coli and purified via His-tag using affinity 
chromatography (3.2.4. of Methods) with the yield of 3-5 mg of the protein from 500 ml of 
bacterial culture. The expression plasmids pET28a(+)ezrin and pET28a(+)ezrinT567D enabled 
efficient expression of the stable proteins.  
The first fluorescent construct designed for the FRET experiments was ezrin fused to YFP 
(N-terminal) and CFP (C-terminal), as the YFP-CFP FRET pair is widely used. Therefore, the 
pET28a(+)YFPEzrCFP plasmid was generated by cut-ligation molecular cloning (3.2.3.2. in 
Methods).  
Attempts to purify YFPEzrCFP from different E.coli strains were not successful. The 
following strains were used: BL21, Rosetta (can use eukaryotic codons which may be 
misread in other E.coli strains), JM110 (Dam and Dcm negative, i.e. lacking metilation on 
ATC and C(A/T)GG), DH5α. It was possible to enrich a His-tagged protein on the Ni-NTA 
affinity column, but SDS-PAGE analysis revealed that it had the mass of 105 kDa, while the 
calculated size of YFPEzrinCFP is about 140 kDa. Western blot analysis of the bacterial 
samples taken 3 hours after expression induction, stained with antibodies against ezrin and 
GFP (suitable for YFP and CFP too), showed that the band of 105 kDa band reacted with 
both antibodies. This indicated that the protein was disrupted before the purification and 
had only CFP or only YFP attached to ezrin: 
 
                            . 
 
 
However, it was possible to obtain the desired protein upon recombinant expression in 
HEK293T eukaryotic cells. HEK293T cells are a popular cell line for protein expression due to 
the presence in their genome of the SV40 large T antigen from Simian Vacuolating virus 40. 
The product of the gene enhances the production of the transfected plasmid, therefore 
contributes to higher recombinant protein yield. To purify YFPEzrCFP from HEK293T cells I 
introduced a His-tag sequence (3.2.3.2. of Methods) into the pEYFPEzrCFP plasmid which I 
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obtained as an intermediate product during the cloning of pET28a(+)YFPEzrCFP for bacterial 
expression. The stably transfected cell line were established by selection with G418 
antibiotic at concentration of 1.4 µg/ml.  
YFPEzrCFP protein purified from HEK293T cells had the correct 140 kDa size as judged by 
SDS-PAGE and Western blot (Fig.10). But the amount of the protein which could be obtained 
from 100 confluent 20-cm plates ranged only from 0.5 to 1 mg. This amount turned out not 
to be not enough for the planned experiments. 
 
 
 
  
 
Fig. 10. Purification of recombinant YFPEzrCFP from HEK293T cells. Anti-ezrin, anti-GFP, anti-His-tag – immunodetection 
with antibodies against His-tag, ezrin and eGFP moieties, SDS-PAGE- coomassie staining of the elution fraction from the 
His-tag affinity column.    
 
 
 
Due to these experimental limitations in obtaining sufficient amount of YFPEzrCFP I 
changed the strategy and generated differently labeled fluorescent ezrin protein. 
Specifically, I used C-terminally GFP-tagged ezrin that could be labeled with chemical 
fluorophore at the N-terminal end. High yields of ezrinGFP were obtained using the 
pET24b(+)EzrinGFP expression plasmid in BL21 E.coli cells. Three to five mg of EzrGFP and 
DGFP each could be purified from 0.5-1 L of bacterial culture as described in 3.3.4. of 
Methods. (Fig.11)  
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Fig.11. Purification of recombinant EzrGFP from E.coli. Anti-ezrin, anti-T7tag – immunodetection with antibodies against 
ezrin and T7-tag, SDS-PAGE- coomassie staining of the elution fraction from the His-tag affinity column. 
 
 
4.2 Liposome pelleting assay: the fluorescent derivatives of ezrin bind to PIP2 
and DOGS-Ni-NTA containing liposomes like the wild type protein 
 
EzrGFP and YFPEzrCFP were tested for binding to two types of liposomes: 1) POPC:PIP2, 
molar ratio 92:8, 2) DOPC:DOGS-Ni-NTA, molar ratio 92:8. Proteins were incubated with the 
liposomes at RT for 1 hour and then the mixture was subjected to ultracentrifugation for 1 
hour at 100krpm. The pellet and supernatant fractions were analyzed by SDS-PAGE. His-
tagged ezrin-wt was included as the control, since it is known to specifically bind to PIP2 (V 
Niggli et al. 1995). Fig. 12 illustrates that both fusion constructs bound to PIP2- and DOGS-Ni-
NTA-containing liposomes (pellet fraction) similar to ezrin-wt. 
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Fig.12. Liposomes pelleting assay, coomassie stained SDS-PAGE.  Letters “s” and “p” stand for “supernatant” and “pellet”, 
“e” – ezrin, “eg” – EzrGFP, “yec” – YFPEzrCFP.  
The values in per cent estimating the amounts of the proteins in the supernatant fractions “s” and in the pellet fractions 
“p”: 
 
1st gel DOGS-Ni-NTA binding 1st gel PIP2 binding 
ezrin   EzrGFP  Ezrin  EzrGFP  
s 36.40% s 5.50% s 50.60% s 57.10% 
p 63.60% p 94.50% p 49.40% p 42.90% 
2d gel DOGS-Ni-NTA binding 2d gel PIP2 binding 
Ezrin  YFPEzrCFP  Ezrin  YFPEzrCFP  
S 9.75% s 22% S 50.90% s 67.20% 
P 90.25% p 78% P 49.10% p 32.80% 
 
Densitometry was performed using Image J analysis software (NIH) for this evaluation. 
 
 
4.3 EzrGFP and DGFP are recruited to the cell membrane in EGF activated A431 
cells similar to endogenous ezrin 
 
A431 cells express high levels of the EGF receptor and, therefore, are a convenient model 
for EGF stimulation experiments. Moreover, ezrin recruitment to the membrane in EGF 
stimulated A431 cells was also reported earlier (A Bretscher 1989). Serum-starved cells, 
overexpressing EzrGFP or DGFP, were stimulated with EGF. The same procedure was carried 
out with non-transfected cells to compare the behavior of the GFP-fused proteins and 
endogenous ezrin. 
Three cell samples were prepared for each protein: 1 - non-starved: here cells were 
cultured in serum rich medium (10% FCS), 2 – starved: here cells were maintained in serum-
free medium, 3 - starved-stimulated: here cells were kept in serum free conditions and then 
stimulated with EGF. All experimental groups of cells were grown simultaneously on glass 
cover slips in 24-well plates, then fixed with PFA and examined under the microscope LSM 
780 (Zeiss).  
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Non-starved and starved samples had few and small actin-positive cell protrusions and 
microvilli, the distribution of EzrGFP and DGFP was mostly cytosolic. The starved-stimulated 
cells revealed a phenotype with many long microvilli and protrusions, and EzrGFP, as well as 
DGFP, were recruited to the cell membrane and accumulated in the rpotrusions. 
Experiments with endogenous ezrin showed a similar results (Fig. 13-15), indicating that the 
C-terminal GFP tag does not affect the behavior of ezrin within the cells. 
Differences between EzrGFP and DGFP were not observed. 
 
1 
 
2 
 
3 
 
 
Fig. 13. EGF stimulation of A431 cells over-expressing EzrGFP.  Cells over-expressing EzrGFP were fixed with PFA and 
analyzed under the microscope following three cases: 1 – cells were cultured in usual conditions with serum, 2 – cells were 
starved in serum-free medium for 5-7 hours, 3 – cells were stimulated with EGF after they were serum-starved. A – EzrGFP, 
B – actin stained with TRITC-phalloidin, C – merge. Scale bar = 10 µm. 
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Fig. 14. EGF stimulation of A431 cells over-expressing DGFP. Cells over-expressing DGFP were fixed with PFA and analyzed 
under the microscope following three cases: 1 – cells were cultured in usual conditions with serum, 2 – cells were starved 
in serum-free medium for 5-7 hours, 3 – cells were stimulated with EGF after they were serum-starved. A – EzrGFP, B – 
actin stained with TRITC-phalloidin, C – merge. Scale bar = 10 µm 
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Fig. 15. EGF stimulation of A431 cells expressing ezrin constitutively. Cells expressing endogenous ezrin were fixed with 
PFA and analyzed under the microscope following three cases: 1 – cells were cultured in usual conditions with serum, 2 – 
cells were starved in serum-free medium for 5-7 hours, 3 – cells were stimulated with EGF after they were serum-starved. 
A – endogenous ezrin visualized with Alexa fluor 647, B – actin stained with TRITC-phalloidin, C – merge. Scale bar = 10 µm.  
 
 
 
The same analysis was performed with HeLa cells. However, the cells showed a 
considerable degree of pre-stimulation: they revealed abundant protrusions already before 
addition of EGF. Thus, the starved and starved-stimulated cells did show massive protrusion 
formation, while non-starved cells showed, as expected, a phenotype with little protrusions 
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and a cytosolic distribution of ezrin. Again, no substantial differences between the different 
constructs and endogenous ezrin were observed, data not shown. 
 
 
4.4 DyLight405EzrGFP is not suitable for FRET analysis 
 
The fluorescence spectra of the chemical fluorophore DyLight405 (as FRET donor) and 
eGFP (as FRET acceptor) meet the requirements for FRET (see Introduction 1.7), although 
this pair was not reported in the literature yet. I used a maleimide modification of 
DyLight405 to label cysteines of ezrin. It is known that ezrin has two cysteines Cys117 and 
Cys284, that can be labeled with chemical fluorophores (Bosk et al. 2011). As these cysteins 
reside in the N-ERMAD, it is likely that FRET can occur between DyLight405, attached to one 
of the cysteines, and the C-terminal eGFP in the closed conformation of ezrin. DyLight405 
labeling was confirmed by UV-illumination of the samples following SDS-PAGE (see Fig.16). 
Emission spectra of DyLight405EzrGFP showed two peaks in response to excitation at 405 
nm with maxima at 425 and 505 nm (Fig. 17). However, experiments with DyLightEzrGFP 
and DyLightDGFP bound via His-tag to DOGS-Ni-NTA containing SSLB (non-activating 
condition) showed no FRET, although fluorescent signals of eGFP and DyLight405 in separate 
channels could be detected (not shown).  
Therefore, I switched to another FRET pair for analizing the conformational activation of 
ezrin. 
 
 
 
 
 
Fig.16. DyLight405 labelling of ezrin and EzrGFP. Purified ezrin and EzrGFP were labeled with DyLight405 as described in 
Methods. After removing free dye, using size-exclusion chromatography, the labeled proteins were subjected to Western 
blot for staining with anti-ezrin antibodies (green bands). The Western blot membranes were also analyzed under UV-light 
to detect the fluorescence of DyLight405 (blue bands on the black background). The blue bands on the light background 
represent coomassie staining of the SDS-PAGE. Bands on all three pictures coincide, confirming that the label is attached. 
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Fig.17. Fluorometric measurements. Emission spectra of DyLight405EzrGFP and DyLight405Ezrin at excitation 
wavelength of 405 nm (excitation of DyLight405). DyLight405EzrGFP showed two emission maxima: DyLight405 and eGFP. 
EGFP fluorescence can be attributed to FRET or minor excitation of eGFP at 400 nm. Emission spectra of EzrGFP at 405 nm 
excitation (molar concentration was close to molar concentration of eGFP moiety in DyLightEzrGFP) was subtracted from 
depicted spectra using FluoroMax software (Instruments S.A.) 
 
 
 
4.5 Cy3EzrGFP shows FRET 
 
EGFP (as FRET donor) and Cy3 (as FRET acceptor) fluorophores are another documented 
FRET pair (Fessenden, 2009; Parsons et al., 2005; Snapp & Hegde, 2006). Therefore, I 
attempted to label the EzrGFP construct at a site in the N-ERMAD with the Cy3 dye. I chose 
a Cy3 NHS ester for labeling, assuming that the position of the cysteines in ezrin might be 
not optimal for the purpose of effective FRET. NHS esters interact with protein amino 
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groups by nucleophilic substitution and are often used for modifying proteins. To achieve 
specific labeling of the N-terminal amino group I established conditions taking into account 
the chemical characteristics of the reaction and dye manufacturer’s recommendations. 
Values for the pKa of the α- and ε-amino groups are 8 and 10.54 respectively. Thus, acidic 
conditions favor labeling of the α-amine but slow down the reaction in general, because at 
low pH amino groups tend to be protonated and, therefore, have decreased nucleophilic 
properties. I established the following settings for optimal α-amino group labeling: pH=6.5, 
low dye to protein molar ratio (1:1) and short reaction time of 4 min.  
The success of the labeling was monitored by running the protein samples on SDS-gels 
and visualizing them with UV-illumination (Fig.18). The efficiency of the labeling (D/P, dye to 
protein ratio) was calculated as described in 3.2.7.3. Methods, see UV-vis spectra in 
Supplement materials (Fig. S1). The D/P varied between different protein batches and 
ranged between 0.7 and 1.1.  
 
 
 
   
                               A                                                                                                                     B 
 
Fig.18. Cy3 labeling. UV-detection. Cy3-labelled eztin, ezrinT567D, EzrGFP and DGFP were run on the SDS-PAGE and the 
gels were analysed under UV-light to detect the fluorescence of Cy3 dye. A – Cy3-labelled proteins, B – UV-illumination of 
non labelled and labeled proteins: 1 - EzrGFP, 2 - Cy3EzrGFP, 3 - ezrin. 70 kDa sign indicates Cy3Ezr and Cy3D, 105 kDa sign 
indicates Cy3EzrGFP and Cy3DGFP. EGFP signal is not detectable here, probably because of denaturating conditions of SDS-
PAGE for the fluorophore. 
 
 
 
To confirm that Cy3 indeed was cross-linked to the N-terminal amino-group, I conducted 
an enzymatic digestion of the labeled proteins with chymotrypsin. Chymotrypsin cuts 
preferably at tryptophan, tyrosine and phenylalanine and is expected to cut 68 times in 
EzrGFP and DGFP and 40 times in ezrin and ezrinT567D (PeptideCutter ExPASy). 
Immunodetection of the control and digested samples with antibodies against ezrin, eGFP 
and the T7-tag, which is present at the very N-terminal part of the constructs (see the 
plasmid maps in Supplemental materials), visualized the chymotrypsin digestion pattern. It 
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was compared with the pattern of Cy3 fluorescence observed via exposing the same blot 
membranes to the UV illumination. This analysis showed that Cy3 dye was bound to two 
sites in the protein: to the very N-terminal amino acid and a, presumably, very active ε-
amino group in the eGFP part, as the Cy3 fluorescence coincided either with anti-T7-tag 
staining or with anti-GFP antibody staining. In the case of Cy3Ezr and Cy3D the Cy3 
fluorescence coincides only with the bands detected with anti-T7-tag antibodies but not 
with anti-ezrin antibodies (the epitope comprises amino acids 479-498 of the ezrin 
sequence) (Fig.19). This suggests that the dye was bound to the very N-terminal part only.  
 
 
 
 
 
 
 
Fig.19. Chymotrypsin digestion of Cy3-labelled proteins. K and D stand for control samples and chymotrypsin digested 
samples, respectively. The green arrow indicates the bands which were detected in Western blot with anti-GFP antibodies 
and under UV-light, the red arrow indicates the bands which were detected with anti-T7-tag antibodies and under UV-light. 
In the control samples: the bands below the Cy3EzrGFP are degradation products. The detection of eGFP and T7-tag with 
corresponding antibodies was combined in one Western blot membrane, the detection of ezrin were conducted on a 
separate Western blot membrane. 
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4.6 Reflectometric Interference Spectroscopy (RIfS) showes binding of the Cy3-
labeled ezrin derivatives to PIP2- and DOGS-Ni-NTA-containing SSLB 
 
RIfS is the physical method for detection of molecular interactions using the interference 
of white light at the surface. The angle of reflected light beam is dependent on the amount 
of molecules bound to the surface. Thus the optical thickness of layer bound can be 
calculated.   
A self-assembled RIfS set-up was used in the experiment (see Methods 3.3.11). Briefly, 
solid supported lipid bilayers (containing 8% PIP2 or 8% DOGS-Ni-NTA in 92% POPC/DOPC, 
molar ratios) were formed on hydrophilic wafers in the RIfS flow chamber as described in 
Methods 3.3.10. The proteins of interest were introduced into the flow system and were 
circulating until saturation of the receptor lipid was achieved. Fig.20 shows the binding 
curves at the respectful proteins concentrations. The recordings obtained were similar to 
the ezrin-wt binding curves (Braunger et al. 2013).  
 
 
(Fig. 20) 
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Fig.20. RIfS measurements. Binding of Cy3EzrGFP, Cy3DGFP, Cy3Ezr and CY3D to solid supported POPC/DOPC bilayers 
containing 8% PIP2 or 8% DOGS-Ni-NTA. The injection of liposomes into the RIfS flow cell induced formation of a lipid 
bilayer on silica wafers what is characterized with the first increase of optical thickness, OT, on the graphs. The following 
addition of the proteins (respective concentrations given) is characterized by the second increase of OT, which showed that 
the proteins bound to the lipid bilayers. 
 
 
 
The binding efficiency, characterized by changes in optical thickness, ΔOT, for all tested 
constructs ranged from 4 to 6. Cy3DGFP and Cy3Ezr bound to DOGS-Ni-NTA-containing SSLB 
and Cy3Ezr, EzrGFP bound to PIP2-containing SSLB showed smaller ΔOT, but the saturation 
was reached in 200 seconds. The saturation was reached in 1500-2000 seconds in the case 
of Cy3EzrGFP and Cy3D binding to DOGS-Ni-NTA-containing SSLB and DGFP to PIP2-
containing SSLB. The ΔOT for these constructs was 5.5-6 units. Other binding curves showed 
fast saturation in 200-500 seconds and ΔOT of 5-6 units (the constructs Cy3EzrGFP, 
Cy3DGFPCy3D on PIP2-containing SSLB; EzrGFP, DGFP on DOGS-Ni-NTA-containing SSLB). All 
Cy3-labeled proteins demonstrated either less steep binding curve or smaller ΔOT on DOGS-
Ni-NTA-containing membranes revealing that Cy3 tag might cause the lesser efficiency of 
the binding to DOGS-Ni-NTA. 
 
 
 
4.7 Fluorescent spectra, FRET in solution 
 
To further characterize the fluorescent ezrin derivatives, theirs emissions spectra were 
recorded on a FluoroMax-2 fluorometer (Instruments S.A.), employing the purified and 
labeled proteins at the concentration of 0.1 µM. 
Cy3Ezr and Cy3D were excited at the excitation maximum of Cy3 – 550 nm, and showed a 
characteristic Cy3 emission with the main peak at 570 nm and a second minor peak at about 
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610 nm; EzrGFP and DGFP constructs also showed typical eGFP emission at the excitation at 
488 nm, the eGFP excitation maximum (Fig. 21). 
 
 
 
 
 
 
 
 
 
Fig. 21. Fluorometric measurements of the single labeled constructs. Emission spectra of Cy3Ezr and Cy3D, following 
excitation at 550 nm (excitation of Cy3), and of EzrGFP and DGFP, following excitation at 488 nm (excitation of eGFP) 
exsibited the characteristic emission peaks for Cy3 and eGFP, respectively.  
 
 
Cy3EzrGFP and Cy3DGFP samples were excited at eGFP excitation maximum, 488 nm (Fig. 
22A). Two emission peaks were detected, corresponding to eGFP emission and Cy3 
emission. This Cy3 emission peak corresponded to the FRET signal, although it might also be 
the result of crossover (or bleed through) due to some minimal Cy3 excitation at 488 nm. 
Excitation of the same constructs but at the Cy3 excitation wavelength resulted in the much 
higher Cy3 fluorescence. The emission spectra of Cy3Ezr and Cy3D, excited at 488 nm, were 
also recorded as controls (Fig. 22B). Detected Cy3 fluorescence was smaller by the factor of 
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10 than in the double labeled samples, excited at 488 nm. The emission of EzrGFP and DGFP 
following excitation at 550 nm was not significant (not shown). Therefore, it is likely that 
some FRET occurs in Cy3EzrGFP and Cy3DGFP in solution, resulting in a Cy3 fluorescence 
following the excitation of eGFP at 488 nm.  
 
 
(Fig. 22) 
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Fig. 22. Fluorometric measurements of FRET. (A) At the excitation at 488 nm Cy3EzrGFP and Cy3DGFP showed two 
emission maxima that correspond to those of eGFP and Cy3; Cy3 fluorescence detected at the excitation at 550 nm of the 
same constructs was higher. (B) Cy3 emission of EzrGFP and DGFP following excitation at 488 nm resulted in the minor 
peaks. 
 
 
 
4.8 Analysis of FRET efficiency on solid supported bilayers 
 
The above characterization revealed that ezrin constructs containing a C-terminal eGFP 
tag and an N-terminal Cy3 label maintain the same properties as wt-ezrin and appear to 
show FRET between the two fluorophores in solution that suggests the closed conformation. 
To determine, whether ezrin’s conformation changes upon binding to PIP2 I next performed 
FRET experiments using fluorescent ezrin constructs bound to artificial lipid membranes 
spread on silica wafers. The samples were inspected in a LSM 710 microscope (Zeiss). At 
first, the concentration of 8mol% of PIP2 in 92% POPC and 8mol% of DOGS-Ni-NTA in 92% 
DOPC was chosen for the SSLB to achieve full surface coverage of the protein (Herrig et al. 
2006). Following protein binding to lipid bilayer FRET was measured by acceptor 
photobleaching. The increase of donor fluorescence after acceptor photobleaching 
demonstrates that the donor became “de-quenched” and able to emit light, whilst the 
acceptor cannot enter the excited state anymore. Fig. 23A shows the typical acceptor 
bleaching experiment. Here, Cy3EzrGFP was bound to solid a supported membrane 
containing 8mol% of DOGS-Ni-NTA, therefore the closed conformation and strong FRET 
were expected. The Region of Interest (ROI) was then subjected to Cy3-acceptor bleaching 
using laser irradiation at 561 nm. This resulted in decreased red fluorescence (Cy3) and 
increased green fluorescence of the donor (eGFP) wich gave evidence of acceptor 
“destruction” and donor being “de-quenched”. Thus it appeared that the Cy3EzrGFP 
construct bound to the DOGS-Ni-NTA-containing SSLB maintained the closed conformation. 
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The drop in Cy3 fluorescence was calculated as difference between the fluorescence before 
and after bleaching and given in per-cent of bleaching intensity. In all the measurements the 
bleaching intensity was kept at 70-80%. 
Fig. 23B shows the result of photobleaching Cy3EzrGFP bound to a lipid membrane 
containing 8mol% PIP2. As PIP2 is an activating factor of ezrin and binding to it is expected to 
lead to conformational changes, a lower FRET intensity was expected. Indeed, the increase 
of eGFP fluorescence was somewhat reduced when Cy3EzrGFP bound to PIP2, as compared 
to DOGS-Ni-NTA. However, FRET still occurred. As ezrin shows high coverage-binding to 
SSLBs containing 8mol% receptor lipids, FRET could result from inter- as well as from intra-
molecular interactions. Therefore, additional controls were included to monitor any inter-
molecular FRET. In these experiments two classes of single-labeled ezrin either containing 
Cy3 ar eGFP label were mixed at a 1:1 molar ratio before binding to a SSLB (Cy3Ezr + EzrGFP 
or Cy3D + DGFP). When these bound proteins were subjected to the bleaching protocol, an 
increase of the donor fluorescence after the acceptor bleaching was observed as weel albeit 
to a lesser extend as compared to experiments employing Cy3EzrGFP (Fig. 24). Thus, the 
FRET measured in the experiments with double-labeled ezrin molecules (Cy3EzrGFP) most 
likely consisted of inter- and intra-molecular FRET. To reduce this “background” signal of 
inter-molecular FRET I switched to lipid membranes containing 4mol% of the receptor lipids, 
thereby reducing ezrin surface coverage. All further measurements were, therefore, 
recorded at these new conditions. Five different ROI were randomly chosen on each wafer 
and FRET was measured by acceptor bleaching. For each of the given conditions the 
following number of acceptor bleaching experiments was recorded: 
Cy3EzrGFP/4mol%DOGS-Ni-NTA – 80 scans, Cy3EzrGFP/4mol%PIP2 – 80 scans, 
Cy3DGFP/4mol%DOGS-Ni-NTA – 80 scans, Cy3DGFP/4mol%PIP2 – 50 scans, 
Cy3Ezr+EzrGFP/DOGS-Ni-NTA – 55 scans, Cy3Ezr+EzrGFP/PIP2 – 35 scans, 
Cy3D+DGFP/DOGS-Ni-NTA – 45 scans, Cy3D+DGFP/PIP2 – 30 scans.  
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Fig.23. Acceptor bleaching FRET of Cy3EzrGFP, bound to SSLB containing 8mol% receptor lipids. A – Cy3EzrGFP bound to 
8mol% DOGS-Ni-NTA-containing SSLB, B – Cy3EzrGFP bound to 8%mol PIP2-containing SSLB. Circled area 1 is ROI (region of 
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interest) after CY3 bleaching, circled area 2 is reference area. The diagram depicts the increase of eGFP fluorescence (green 
line) and the decrease of Cy3 fluorescence (red line), numbers 1 and 2 correspond to ROI and reference area, respectively. 
The marks at the X axis indicate the start-time and the end-time of the bleach. EGFP fluorescence increase after bleaching 
of Cy3 appears to be less in case of the protein bound to PIP2, but a firm conclusion can only be made after statistical 
analysis of series of experiments. The brighter spots most likely represent aggregates of the protein. ROI avoiding such 
spots were chosen. Scale bare = 5 µM. Microscope images for other constructs are shown in Supplemental materials, Fig. 
S2. 
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Fig. 24. Acceptor bleaching FRET of the mixture of two single-labeled proteins (Cy3Ezr+EzrGFP), bound to SSLB 
containing  8mol% receptor lipids. A – Cy3Ezr+EzrGFP bound to 8mol% DOGS-Ni-NTA-containing SSLB, B – Cy3Ezr+EzrGFP 
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bound to 8%mol PIP2-containing SSLB. Circled area 1 is ROI (region of interest) after CY3 bleaching, circled area 2 is 
reference area. The diagram depicts the increase of eGFP fluorescence (green line) and the decrease of Cy3 fluorescence 
(red line), numbers 1 and 2 correspond to ROI and reference area, respectively. The marks at the X axis indicate the start-
time and the end-time of the bleach. EGFP fluorescence increase after bleaching of Cy3 appears to be less in case of the 
protein bound to PIP2, but a firm conclusion can only be made after statistical analysis of series of experiments. The 
brighter spots most likely represent aggregates of the protein. ROI avoiding such spots were chosen. Scale bare = 5 µM. 
Microscope images for other constructs are shown in Supplemental materials, Fig. S2. 
 
 
 
The microscopy scans were processed in ImageJ using FRETcalc plugin which applies 
pixel-by-pixel analysis and accounts for donor “de-quenching” and bleaching efficiency. Such 
normalizing allows comparing FRET between samples on different wafers, disregarding 
minor variations in overall signal intensity and protein binding.  
Using this processing tool and analyzing many individual scans on the different wafers, I 
determined the effect of receptor lipids for all constructs and also compared double-labeled 
proteins with controls employing the mixture of two single-labeled (Cy3 or GFP) derivatives. 
The %FRET (FRET efficiency), calculated with FRETcalc-ImageJ, significantly decreased for 
constructs bound to PIP2 (mean=18.74879) as compared to contracts bound to DOGS-Ni-
NTA (mean= 21.63225), p=9.49e-15. %FRET was almost two times lower for the control 
samples (Cy3Ezr+EzrGFP and Cy3D+DGFP), mean=12.12861, than for the double-labeled 
proteins (Cy3EzrGFP and Cy3DGFP), mean=23.93346, p=2.2e-16. P-values were obtained by 
applying Anova type ll test in R-statistics software on the modeled data which accounts for 
all conditions of the experiment. The fact that repetitions were carried using proteins with 
different labeling efficiency was also considered in this modeling by introducing it as 
another factor in line with the following factors: receptor lipid type, protein type, double 
labeled/control group. 
The box plot in Fig. 25 represents an overview of the series of different experiments. The 
initial measurements with 8mol% receptor lipids were conducted with a relatively small 
number of samples. They are included here to demonstrate that %FRET mean values, ?̅?, are 
similar to those obtained in measurements with 4mol% receptor lipids and, apparently, 
have great “noise” intra-molecular FRET together with inter-molecular FRET. 
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Fig. 25. Summary of FRET-CLSM measurements. Mean values are shown next to the boxes. A: Experiments on SSLB 
comtaining 8mol% receptor lipids. Here, only the Cy3DGFP construct showed a decrease in %FRET when bound to PIP2, as 
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compared to the case when bound to DOGS-Ni-NTA. B: Experiments on SSLB with 4mol% receptor lipids. %FRET for control 
constructs (mixtures of two single-labeled protein species) were significantly lower than for double-labeled proteins, 
p=2.2e-16. The decrease in FRET upon binding to PIP2- as compared to DOGS-Ni-NTA-containing lipid membranes was 
significantly lower in the case of wild type as compared to phosphomimicking constructs. 
 
 
 
To estimate the differences between individual groups and compare the wt-constructs to 
mutant constructs, the delta of mean for each case were calculated using the following 
formula: 
 
                                  𝜎𝑁𝑖−𝑃𝐼𝑃2 = ?̅?𝑁𝑖 − ?̅?𝑃𝐼𝑃2 ±√𝑆𝐸𝑁𝑖
2 + 𝑆𝐸𝑃𝐼𝑃2
2  
 
where δNi-PIP2 is the difference in %FRET between proteins bound to DOGS-Ni-NTA- and PIP2-
containing lipids bilayers, ?̅?Ni and ?̅?PIP2 are %FRET averages and SENi and SEPIP2 represent 
standard errors. The indexes Ni and PIP2 refer to cases where proteins were bound to DOGS-
Ni-NTA- and PIP2-containing lipids bilayers, respectively.  
Standard errors were calculated using the following formula: 
 
𝑆𝐸 = √(
𝜎𝑁𝑖
√𝑛𝑁𝑖
)2 + (
𝜎𝑃𝐼𝑃2
√𝑛𝑃𝐼𝑃2
)2 
 
where nNi and nPIP2 are number of measurements for each case.  
The δNi-PIP2 value for Cy3EzrGFP is 1.93±0.11 and for Cy3DGFP is 9.26±0.62.                                         
For Cy3Ezr+EzrGFP this value is -1.59±0.08 and for Cy3D+DGFP it is 3.29±0.19. 
The data analysis suggested that inter-molecular FRET was significantly lower than intra-
molecular FRET, interestingly, double-labeled proteins and mixture of single-labeled 
proteins showed similar tendency towards bigger decrease of %FRET when bound to PIP2-
containing SSLB. 
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5 Discussion 
 
 
Ezrin serves in the cells as an intermediary between plasma membrane and cytoskeleton 
during cells movement, division and formation of apical actin-rich structures. Its 
disregulation leads to severe consequences, for example, polarity loss in developing 
embryo, increase of metastatic mobility in cancer cells, and disruption of microvilli 
arrangement (Fehon, McClatchey, and Bretscher 2010). The transition between the inactive 
and active state of ezrin, essential for its functioning, is thought to be mediated by PIP2 
binding at the membrane and phosphorylation at the conservative threonine 567. FRET 
experiments using solid supported lipid bilayers (SSLB) were performed in this work to 
elucidate the mechanism of ezrin conformational changes and correlation between the two 
activating factors. These experiments are the first demonstration of FRET with the use of the 
double-labeled fluorescent ezrin constructs bound to SSLB. The in vitro model applied in this 
work offers the advantage of tightly controllable activation conditions, as compared to 
cellular in vivo models. The combination of ezrin-wt and ezrin T567D constructs that were 
analyzed on PIP2- and DOGS-Ni-NTA-containing supported membranes were explored here 
in the FRET studies. It was demonstrated that the phosphomimicking mutation and binding 
to PIP2 together caused the most pronounced conformational changes in ezrin.  
S100P protein as activation factor of ezrin is not discussed here as it can be considered as 
analogous to the PIP2 binding and, supposably, changes the protein conformation in a 
similar way. The unphosphorylatable ezrin T567A mutant was also excluded from the 
experiments as it had not shown significant differences to ezrin wild type in any conditions 
investigated (Bosk et al. 2011; Braunger et al. 2013).  
 
 
5.1 GFP-tag does not change properties of ezrin in the cells and in in vitro 
binding assays 
 
Two ezrin constructs fused with different flourescent proteins were generated and used 
in the thesis: YFPEzrCFP, human ezrin fused with N-terminal YFP and C-terminal CFP tags; 
and EzrGFP, human ezrin with C-terminal GFP. GFP-tagged ezrin-wt (EzrGFP) and also the 
T567D mutant (DGFP) could be successfully expressed BL21 strain of E.coli and purified via 
the His-tag. Recombinant expression and especially purification of the proteins fused with a 
fluorescent protein is not always a trivial procedure, as GFP (or its variants) can impede 
folding process and induce protein degradation. This could explain that YFPEzrinCFP was 
impossible to purify from BL21 bacterial cultures, as only a truncated His-tagged protein 
could be eluted from the beads functionalized with Ni-NTA. This truncated protein was 
detected also in immunoblots of E.coli lysates using anti-ezrin and anti-GFP antibodies (that 
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also recognize YFP and CFP) indicating that the integrity of YFPEzrCFP was already disturbed 
within the bacterial cells. The possible reason, besides abnormal folding, could be the 
difference in codon usage between mammalian cells and bacteria. Rosetta strain of E.coli is 
created to avoid such incompatibility. It has seven tRNAs not typical for E.coli that enables 
the bacterial translational machinery to recognize amino acids adapted for eukaryotic 
expression. As eYFP and eCFP sequences used for molecular cloning of the 
pET28a(+)YFPEzrCFP plasmid were adopted from eukaryotic plasmids, it is possible that 
YFPEzrCFP can be problematic for the expression in bacteria. (It is important to notice, 
pE28a(+)ezrin and pE24b(+)eGFP plasmids for prokaryotic expression were used for the 
design of the pET28a(+)EzrGFP/DGFP plasmid). Therefore, the Rosetta strain was exploited 
here, but still only the truncated protein could be obtained. The phenomenon of intrinsic 
transcription termination in prokaryotes could also impede the recombinant expression: 
specific cytosine-guanine rich RNA spikes followed by several uracils can cause stalling and 
subsequent dissociation of the RNA polymerase complex. So far, there are no reports of 
YFP-CFP double-labeled proteins expressed recombinantly in bacteria, although an 
expression of a YFP-ezrin-CFP construct in HeLa cells was performed successfully by Zhu et 
al. (Zhu, Liu, and Forte 2005). Therefore mammalian HEK293T cells were chosen for the 
expression of YFPEzrCFP, as this cell line is often used for recombinant protein expression 
and purification, the pE-HisTag-YFPEzrCFP plasmid was designed for the purpose. The 
plasmid carried the G418 antibiotic resistance gene, and HEK293T cells possess the same 
antibiotic resistance. Nevertheless, it was still possible to obtain stably transfected cell lines 
with the use of the relatively high G418 concentrations (1.4 µg/ml). For comparison, HEK293 
cell line, lacking G418 resistance, are usually killed by 200-500 µg/ml of the antibiotic 
(http://www.invivogen.com/PDF/G418_TDS.pdf). Although the sensitivity of the selected 
clones to G418 decreased within 6-8 weeks leading to domination be the plasmid-free cells 
(monitored by recording the YFP-signal). Repetitive subcloning was necessary to keep the 
pEYFPEzrinCFP-HEK293T cell line. Intact HisTag-YFPEzrCFP protein was purified, as revealed 
by its integrity shown in Western blot analysis (Fig. 10). However, the yield was too low for 
the experiments planned. Therefore, only EzrGFP and DGFP purified from E.coli BL21 strain 
were used further in this work.  
The behavior of EzrGFP and DGFP was tested in the cells. Figures 13 to 15 depict EGF 
stimulation experiments with A431 cells. Upon stimulation cells formed membrane 
protrusions and EzrGFP and DGFP demonstrated accumulation at these protrusions; similar 
behavior was observed for ezrin endogenously expressed by A431 cells. Ezrin labeled with 
GFP at the C-terminus demonstrated a cell distribution similar to endogenous ezrin also in 
NIH3T3 fibroblasts and HtTA-1 cells as shown by Amieva et al. and Henry at al. (Amieva et al. 
1999; Henry, Gonzalez Agosti, and Solomon 1995). Interestingly, Zhu et al. reported that 
YFP-ezrin (N-terminal tag) had a tendency of cytoplasmic localization in HeLa cells, while 
ezrin-CFP (C-terminal tag) and the wild type protein concentrated at the membrane (Zhu, 
Liu, and Forte 2005).  Apparently, the N-terminal fluorescent protein tag, in contrary to the 
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C-terminal tag, can impede PIP2-binding. Quantification of EzrGFP and YFPEzrGFP binding to 
PIP2, in comparison to DOGS-Ni-NTA binding, was done here by analyzing the results of 
liposomes pelleting assay. The co-sedimentation tendency suggested that the two 
fluorescent chimeras and ezrin-wt bind more efficiently to the liposomes containing DOGS-
Ni-NTA lipids, than to those containing PIP2 (Fig. 12). That reflects an easy accessibility of the 
N-terminal His-tag in all tested proteins. In the case of the binding to PIP2-containing 
liposomes approximately 42% of EzrGFP and 50% of ezrin-wt were detected in the pellet 
fractions, indicating that the GFP tag only slightly inhibits PIP2 binding of ezrin. In contrast, 
only approximately 32% of YFPEzrCFP bound to PIP2-containing liposomes. Thus, the YFP 
and CFP tags together had more influence on the ability of ezrin to bind PIP2 but did not 
supress it completely. In the experiments performed by Zhu et al. in HeLa cells the majority 
of YFP-ezrin did not bind to the membrane. Such discrepancy could be explained by the 
higher concentration of the PIP2 lipid in artificial liposomes than in the cell membrane. 
 
5.2 Properties of Cy3EzrGFP and DyLight405EzrGFP as FRET constructs 
  
Easy accessibility of commercial chemical fluorophores allowed choosing different FRET 
pairs for eGFP. Two fluorescent dyes, Cy3 NHS ester and DyLight405 maleimide, were tested 
here. The chemical targets of maleimides are cysteine residues of proteins; molecules 
functionalized with NHS ester moieties can react with amino-groups. For the design of ezrin-
FRET construct it was required to attach the second fluorophore to the N-terminal end of 
EzrGFP. In the case of Cy3 NHS ester, the preferable labeling of the α-amino group was 
achieved by performing the reaction at acidic pH: as α-amino group has the properties of a 
stronger acid than side chain amino groups, it will react with esters in acidic conditions more 
efficiently than the other. The labeling was confirmed by reading absorption spectra of the 
resulting products (see Supplemental materials, Fig. S1). To confirm that the label had 
attached specifically to the N-terminus, the product was digested with chymotrypsin and 
the resulting fragments were probed with anti-T7-tag antibodies in Western blots (the T7-
tag was encoded between the His-tag and ezrin). Illumination of this Western blot 
membrane with UV-light revealed that Cy3-fluorescent bands coincided with the anti-T7-tag 
signal indicating that the N-terminal amino group was specifically labeled (Fig. 19). The 
obtained Cy3EzrGFP and Cy3DGFP constructs were also tested with respect to their binding 
to PIP2 and DOGS-Ni-NTA lipids using RIfS (Reflectometric Interference Spectroscopy).  
 
RIfS can estimate amount of proteins bound to solid supported membranes by detection 
and analysis of multiple reflection of white light from the sample. Fig. 20 shows binding of 
the Cy3-labeled ezrin derivatives to PIP2- and DOGS-Ni-NTA-containing SSLB. The binding of 
EzrGFP and DGFP proteins was also measured to compare the behavior of the double-
labeled and the single labeled constructs. The value obtained in this thesis is in the same 
range with the RIfS measurements performed by Braunger et al. with ezrin-wt (Braunger et 
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al. 2013). EzrGFP and DGFP showed attenuated binding to PIP2 lipids, but at the same time 
Cy3EzrGFP and Cy3DGFP had normal binding curves for PIP2-containig SSLB. To summarize, 
Cy3 and GFP tags did not have strong effect on ezrin binding to PIP2- or DOGS-Ni-NTA-
containing solid supported membranes measured by RIfS technique, as all the constructs 
tested by RIfS could form stable protein layer after 40 minutes maximum. Correspondingly, 
binding of the proteins to SSLB for the further FRET experiments were performed at 
incubation time of more than 12 hours to avoid any binding deficiencies. Ezrin wild type and 
phosphomimicking mutants did not reveal any differences in binding in the RIfS trials. 
 
Ezrin has two cysteins in N-ERMAD at position 117 and 284 that are apparently available 
for chemical modification (Bosk et al. 2011); they could be potential loci for attachment of 
DyLight405 for creating a construct for intra-molecular FRET. For that reason the 
DyLight405EzrGFP construct was also tested in this work. FRET was not detected in 
experiments with DyLight405EzrGFP bound to SSLB via its His-tag. The explaination could be 
the unfortunate positioning of the DyLight405-donor on the DyLight405EzrGFP molecule 
bound to SSLB and/or an exceeding of the Forster distance; or else DyLight405 and GFP do 
not possess qualities of a FRET pair. FRET measured by fluorometry (Fig. 17) was probably 
caused by the direct excitation of the acceptor. Moreover, DyLight405-eGFP has not been 
mentioned anywhere in the literature as the successful FRET pair.  
 
 
5.3 PIP2 binding and threonine 567 phosphorylation contribute to 
conformational change in ezrin simultaneously  
 
FRET experiments with the fluorescent ezrin were first performed in solution. FRET signal 
was observed at the excitation of Cy3EzrGFP and Cy3DGFP at 488 nm (the donor excitation 
wavelength). Similar to this, FRET signal in solution was recorded by Zhu et al in the lysates 
of HeLa cells expressing YFP-ezrin-CFP construct (Zhu, Liu, and Forte 2005). The precise FRET 
calculations were made during the FRET-LSM experiments with the fluorescent ezrin 
constructs bound to the solid supported membranes, where FRET was also confirmed by 
acceptor bleaching. The acceptor bleaching technique was used in this study, as there are 
no time restrictions; the chosen acceptor, the Cy3 fluorescent dye, is easy to bleach but 
stable enough for longer measurements.  
The first experiments were conducted with 8mol% of the receptor lipids PIP2 and DOGS-
Ni-NTA in the SSLB (Fig. 23, 24). They showed high levels of inter-molecular FRET signals, 
apparently occurring between neighboring molecules. One ezrin molecule occupies at least 
70x70 Å area on the SSLB (the size of the N-ERMAD  (K Hamada et al. 2000)) and the area 
per lipid for PIP2 equals 70 Å2  (Janke et al. 2008), for DOGS-Ni-NTA it is around 65 Å2 (Körner 
et al. 2013). Assuming that the protein concentration is large enough to occupy all binding 
sites on the artificial membranes, it is possible to calculate that at the receptor lipids 
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concentration of 8mol% at least 6 molecules of PIP2 or DOGS-Ni-NTA are arranged 
underneath one ezrin molecule. At a concentration of 4mol% - at least 3 lipid molecules 
could be associated with the bound ezrin. On practice ezrin showed poor binding to solid 
supported membranes with PIP2 concentration less than 3mol% (Herrig et al. 2006). 
Therefore, the protein density on the lipid surface is high enough for inter-molecular FRET 
to occur at the available experimental conditions. Thus, 4mol% concentrations of PIP2 and 
DOGS-Ni-NTA were accepted as most reasonable for the experiments in this study.  
To determine the contribution of inter-molecular FRET signal under these conditions, 
equimolar mixtures of Cy3Ezr+EzrGFP and Cy3D+DGFP were used as controls. In this case 
the measured FRET efficiency was by a factor of two lower than that for the double-labeled 
constructs (Fig. 25). Thus, in the case of the double labeled Cy3EzrGFP and Cy3DGFP the 
FRET signal measured comprised the sum of intra- and inter-molecular FRET, i.e. FRET 
between Cy3 and eGFP of a single molecule and of two neighboring molecules. Similarly, 
inter- and intra-molecular FRET signals were detected by Zhu et al. in HeLa cells expressing 
YFP-Ezrin-CFP (Zhu, Liu, and Forte 2005). In this paper the level of inter-molecular FRET was 
significantly smaller than that of intra-molecular FRET, too. The question of conformational 
changes was not investigated in their experiments, since PIP2 binding and phosphorylation 
rate could not be controlled due to complex processes which occur in the cell.  
  
Acceptor bleaching experiments, conducted with ezrin derivatives (wild type and T567D 
mutant) bound to PIP2-containing SSLB (thus presumably in a partly activated conformation) 
and proteins bound to DOGS-Ni-NTA-containing SSLB (thus presumably in a non-activated 
state) revealed that PIP2 binding had the most prominent conformational effect on the 
pseudo-phosphorylated ezrin constructs (T567D constructs). A drop in the FRET signal most 
likely represents an increase in the distance between N-terminal Cy3 and C-terminal eGFP, 
i.e. a conformational change caused by the dissociation of ezrin’s N-ERMAD and C-ERMAD. 
The decrease in FRET between Cy3DGFP bound to DOGS-Ni-NTA and to PIP2 constituted 
9.26% ±SE=0.62, whereas Cy3EzrGFP only showed a minor change in FRET efficiency 
between its PIP2-bound and DOGS-Ni-NTA bound states, 1.93% ±SE=0.11 (Fig. 24). The 
decrease in the FRET efficiency for the mixture of Cy3D+DGFP was estimated to be 3.29% 
±SE=0.19; and the mixture Cy3Ezr+EzrGFP even demonstrated a slight increase in FRET 
efficiency when bound to PIP2-containing membranes, the value was -1.59% ±SE=0.085. 
These data are in agreament with the study by Bosk et al., in which the ezrin T567D mutant, 
too, revealed the most stricking increase in acting binding efficiency when immobilized on 
PIP2 containing SSLB. In this case actin binding can be veiwed as an indicator of the 
conformational change as it is only observed in the active state (Bosk et al. 2011). The 
colloidal probe studies by Braunger et al. (Braunger et al. 2014) showed the different aspect 
of synergism of the activation factors, in particular, that the ammount of ezrin-actin bonds 
was strongly increased upon PIP2 binding, while the phosphomimicking state of the protein 
caused only minor changes in the ability to bind actin. Interestingly, the strenght of a single 
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ezrin-actin bond was found equal in all experemintal conditions and estimated around 50 
pN (Braunger et al. 2014). Altogether, these findings are in line with the two step ezrin 
activation model: 1 - PIP2 binding is required to make the C-terminal threonine accessible for 
phosphorylation, 2 – threonine phosphorylation induces and/or stabilizes the active state. 
But it seems that the role of PIP2 might be expanded, as the conformation of the ezrin 
phosphomimicking mutant bound to DOGS-Ni-NTA-containing SSLB did not seem to be 
different from that of the wild type construct in the same conditions, judging from the FRET 
experiments. Probably that PIP2 binding, together with the C-terminal threonine 
phosphorylation, contribute to “pushing” N-ERMAD away from C-ERMAD. 
 
Membrane bound ezrin was characterized to be often present in an oligomeric, non 
active form (Fritzsche et al., 2014;  Zhu et al., 2005). This is in agreement with the report of 
Coscoy et al. about the excistence of an intermediate ezrin state. They proposed that four 
ezrin forms excist in the cell: an inactive cytoplasmic form; ezrin bound to the membrane via 
PIP2, this could be present in oligomeric forms; ezrin bound to the membrane and actin, i.e. 
fully activated; and an ezrin intermediate form that can transiently interact with actin only 
for a short time (Coscoy et al., 2002; Fritzsche, Thorogate, & Charras, 2014). This transient 
interaction is supposed to be maintained by additional acting binding sites which were 
discovered in the N-ERMAD (Roy, Martin, and Mangeat 1997), see also Fig.26.  
The ability of the intermediate, not fully activated form of ezrin to bind actin filaments 
explains the relatively high actin binding activity of the wild type ezrin in the study of 
Braunger et al. It is probable that the exploited in their work conditions promoted the 
formation of actin-ezrin bonds because of the excess of actin filaments and ezrin molecules 
in the system. Thus, a minor contribution from the wild type form could be overstated at 
some extend. Thus, even inactive ezrin T567A mutant attached to SSLB was reported to 
have some actin binding activity (Bosk et al. 2011). The FRET experiemnts performed in this 
thesis reflect not the binding activity, the quantitative characteristics, but the 
conformational state of ezrin molecule, a qualitative feature. Although the calculation of 
FRET efficiency in this work was also complicated because of the high density of the FRET 
units on the lipid surface. Our data suggest that a fully open ezrin conformation is 
achievable only in the simultaneous presence of PIP2 and C-terminal threonine 
phosphorylation. The ezrin-wt constructs showed little differences between PIP2-bound and 
DOGS-Ni-NTA-bound forms, suggesting that PIP2 binding alone is not sufficient to fully 
disrupt the N-C association. The observed decrease in FRET for the wild type ezrin bound to 
PIP2-containing lipid membranes could also be explained by the excistance of the 
intermediate ezrin form. The unstaible conformational changes induced by PIP2 binding 
could still cause moving the FRET donor away from the FRET acceptor at some extent. 
This thesis and other recent studies demonstrated that the activation mechanism of ezrin 
is a rather complex process regulated by many factors. PIP2 mediates cell membrane 
localization of ezrin, its binding makes threonine 567 available for kinases (Rho kinase, PKC) 
DISCUSSION 
 
79 
 
and the phosphorylation at this residue in turn leads to dissociation of C-ERMAD and N-
ERMAD of ezrin. The fully open conformation of ezrin is then stabilized by binding to actin 
filaments via C-ERMAD and interaction with membrane proteins via N-ERMAD (CD44, PDZK1 
ect.). Some membrane proteins may form signalling complexes with ezrin providing highly 
tuned coordination of membrane-cytoskeleton interactions. 
Phosphorylation/dephosphorylation cycles at threonine 567 as well as regulation of PIP2 
concentration (e.g. by phospholipase C) in the membrane are also important factors that 
influence the ezrin activation-deactivation processes. The existance of inactive or partually 
activated ezrin at the membrane suggests that C-terminal phosphorylation acts as a trigger 
that switches membrane bound ezrin into an active, membrane-and-actin bound state; this 
allows regulation of cell cortex organization in a fast and reversible manner. However, 
further experiments that combine the FRET method established here and AFM technique of 
measuring adhesion forces of ezrin-actin binding are required to confirm the hypothesis of 
the intermidiate ezrin state. In particular, protein samples that demonstrated FRET when 
bound to SSLB could be directly tested on the ability to bind actin. Actin filaments attached 
to the AFM cantilever would be a convenient model for this. The correlation between FRET 
efficienies and actin binding efficiencies detected from the same samples could elucidate 
the question of the correlation between the ezrin conformation and its interaction with 
actin filaments. Another factor of ezrin activation should be tested in the future: S100P 
protein that was proposed as the third activation factor and the competitor of PIP2  
(Austermann et al. 2008).  
The investigation of factors that recruite ezrin to the membrane is another future 
direction of research into the ezrin activation mechanism. It is important to know what 
stimuli initiate and also supress ezrin binding to the membrane and actin as well as to 
understand the events successive to the interaction of ezrin with its binding partners. For 
example, there are some evidences suggesting that ezrin may participate in actin 
polimerization (Crepaldi, Gautreau, Comoglio, Louvard, & Arpin, 1997; Naba, Reverdy, 
Louvard, & Arpin, 2008). Moreover, many studies showed an involvement of ezrin in cellular 
signalling via its membrane interactions, but underlying mechanisms is not fully understood. 
The future investigations in this direction together with additional findings about the 
mechanism of ezrin activation will provide us with the important knowledge in the field of 
actin-membrane interaction.  
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Fig. 26. Proposed scheme for ezrin conformational states in the cell. Inactive ezrin molecules can relocolize from the 
cytoplasm to the membrane (1), where they bind to PIP2 molecules and are capable of transient actin binding. Few 
proteins were shown to bind to C-ERMAD of not fully activated ezrin, for example SCYL3 and FHOD1. Ezrin can then transit 
to a membrane-and-actin bound state (2) which is characterized by threonine 567 phosphorylation in ezrin and its 
interactions with membrane proteins via N-ERMAD and actin filaments via C-ERMAD. Membrane proteins can bind directly 
to ezrin or via the EBP50 protein. Arrows indicate other processes with ezrin participation.  
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Supplemental materials 
 
 
S1. Absorbtion spectra of ezrin fluorescent constructs 
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Fig. S1. Absorption spectra of Cy3EzrGFP, Cy3DGFP, Cy3Ezr, Cy3D and EzrGFP, DGFP.  1 – maximum absorption peak of 
aromatic amino acids of the proteins at 280 nm, 2 – maximum absorption peak of Cy3 dye at 550 nm, 3 – maximum 
absorption peak of eGFP at 488 nm. The spectra were read using  spectrophotometer UV-visible 50scan Varian. 
 
 
 
S2. Fluorescent images of acceptor bleaching FRET 
 
Fig S2A. Acceptor bleaching FRET of the proteins bound to SSLB containing  8mol% receptor lipids. Circled area 1 is ROI 
(region of interest) after Cy3 bleaching, circled area 2 is reference area. The diagram depicts the increase of eGFP 
fluorescence (green line) and the decrease of Cy3 fluorescence (red line), numbers 1 and 2 correspond to ROI and 
reference area, respectively. The marks at the X axis indicate the start-time and the end-time of the bleach. The brighter 
spots most likely represent aggregates of the protein. ROI avoiding such spots were chosen. Scale bare = 5 µM. 
 
Cy3EzrGFP bound to SSLB containing 8mol% DOGS-Ni-NTA 
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Cy3EzrGFP bound to SSLB containing 8mol% PIP2 
 
 
 
 
Cy3DGFP bound to SSLB containing 8mol% DOGS-Ni-NTA 
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Cy3DGFP bound to SSLB containing 8mol% PIP2 
 
 
 
 
Cy3Ezr+EzrGFP bound to SSLB containing 8mol% DOGS-Ni-NTA 
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Cy3Ezr+EzrGFP bound to SSLB containing 8mol% PIP2 
 
 
 
 
Cy3D+DGFP bound to SSLB containing 8mol% DOGS-Ni-NTA 
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Cy3D+DGFP bound to SSLB containing 8mol% PIP2  
 
 
 
 
Fig S2A. Acceptor bleaching FRET of the proteins bound to SSLB containing  8mol% receptor lipids. Circled area 1 is ROI 
(region of interest) after Cy3 bleaching, circled area 2 is reference area. The diagram depicts the increase of eGFP 
fluorescence (green line) and the decrease of Cy3 fluorescence (red line), numbers 1 and 2 correspond to ROI and 
reference area, respectively. The marks at the X axis indicate the start-time and the end-time of the bleach. The brighter 
spots most likely represent aggregates of the protein. ROI avoiding such spots were chosen. Scale bare = 5 µM.  
 
 
 
 
 
 
 
 
 
 
 
Next: 
Fig S2B. Acceptor bleaching FRET of the proteins bound to SSLB containing 4mol% receptor lipids. Circled area 1 is ROI 
(region of interest) after Cy3 bleaching, circled area 2 is reference area. The diagram depicts the increase of eGFP 
fluorescence (green line) and the decrease of Cy3 fluorescence (red line), numbers 1 and 2 correspond to ROI and 
reference area, respectively. The marks at the X axis indicate the start-time and the end-time of the bleach. The brighter 
spots most likely represent aggregates of the protein. ROI avoiding such spots were chosen. Scale bare = 5 µM. 
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Cy3EzrGFP bound to SSLB containing 4mol% DOGS-Ni-NTA 
 
 
 
 
Cy3EzrGFP bound to SSLB containing 4mol% PIP2 
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Cy3DGFP bound to SSLB containing 4mol% DOGS-Ni-NTA 
 
 
 
 
Cy3DGFP bound to SSLB containing 4mol% PIP2 
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Cy3Ezr+EzrGFP bound to SSLB containing 4mol% DOGS-Ni-NTA 
 
 
 
 
Cy3Ezr+EzrGFP bound to SSLB containing 4mol% PIP2 
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Cy3D+DGFP bound to SSLB containing 4mol% DOGS-Ni-NTA 
 
 
 
 
 
Cy3D+DGFP bound to SSLB containing 4mol% PIP2 
 
 
 
Fig S2B. Acceptor bleaching FRET of the proteins bound to SSLB containing 4mol% receptor lipids. Circled area 1 is ROI 
(region of interest) after Cy3 bleaching, circled area 2 is reference area. The diagram depicts the increase of eGFP 
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fluorescence (green line) and the decrease of Cy3 fluorescence (red line), numbers 1 and 2 correspond to ROI and 
reference area, respectively. The marks at the X axis indicate the start-time and the end-time of the bleach. The brighter 
spots most likely represent aggregates of the protein. ROI avoiding such spots were chosen. Scale bare = 5 µM. 
 
 
 
S3. Plasmid maps (next) 
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S3. Plasmid maps 
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Abbreviations  
 
A 
AB 
ABS  
AFM  
APC  
AU  
Ca2+ 
C-ERMAD  
CLSM  
C-N association 
 
Cy3EzrGFP 
Cy3DGFP 
ddH2O  
 
DGFP 
 
DOGS-NTA-Ni 
 
 
DOPC 
 
e.g.                                                                                 
EGF  
eGFP 
ERM  
EzrGFP 
EzrinT567D 
Ezrin-wt 
F-actin  
FERM  
FLIM 
FRAP 
FRET 
G418 
h  
Ampere 
Antibody 
Actin binding site 
Atomic force microscopy 
Antigen presenting cell 
Arbitrary unit 
Calcium ion 
C-terminal ERM association domain 
Confocal laser scanning microscopy 
Association between C-terminus and N-
terminus of a protein 
Cy3 crosslinked EzrGFP 
Cy3 crosslinked DGFP 
Double‐destilled H2O (Millipore filtered and 
autoclaved) 
EzrinT567D-eGFP, phosphomimicking ezrin 
mutant T567D fused with C-terminal eGFP 
1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-
carboxypentyl)iminodiacetic acid)succinyl] Ni 
salt 
1,2-dioleoyl-sn-glycero-3-phosphocholine 
 
Exempli gratia (for example) 
Epidermal growth factor 
Enhanced green fluorescent protein 
Ezrin, radixin, moesin protein group 
Ezrin fused with C-terminal eGFP 
Ezrin phosphomimicking mutant 
Wild type ezrin 
Filamentous actin 
Four-point-one-ERM 
Fluorescence-lifetime imaging microscopy 
Fluorescence recovery after photobleaching 
Förster resonance energy transfer 
Geneticin, antibiotic 
hour 
  
IF  
IS  
kDa  
LSM 
m  
M  
min 
n  
N-ERMAD  
OD  
PH domain  
PI  
PIP2  
POPC  
 
QCM  
RIfS  
rpm  
RT  
SDS-PAGE  
 
SE 
SSLB 
T567A 
T567D, T567E 
TCR  
tRNA  
UV 
UV-vis 
V  
YFPEzrCFP 
 
μ  
°C  
 
Immunofluorescence 
Immunological synapse 
kilo Dalton 
Laser scanning microscope 
milli (thousandths) 
molar 
minute 
nano (billionth) 
N-terminal ERM association domain 
Optical density 
Pleckstrin homology domain 
Phosphatidylinositol 
Phosphatidylinositol-4,5-bisphosphate 
1-Palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine 
Quartz crystal microbalance 
Reflectometric interference spectroscopy 
Rounds per minute 
Room temperature 
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Standard error (statistics) 
Solid supported lipid bilayers 
Ezrin unphosphorylatable mutant 
Ezrin phosphomimicking muatnts 
T cell receptor 
Transfer ribonucleic acid 
Ultraviolet light 
Ultraviolet-visible 
Volt 
Ezrin fused with N-terminal eYFP and C-
terminal eCFP 
micro (millionth) 
Degree Celsius 
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